1
|
Nadarajah R, Ludman P, Appelman Y, Brugaletta S, Budaj A, Bueno H, Huber K, Kunadian V, Leonardi S, Lettino M, Milasinovic D, Gale CP, Budaj A, Dagres N, Danchin N, Delgado V, Emberson J, Friberg O, Gale CP, Heyndrickx G, Iung B, James S, Kappetein AP, Maggioni AP, Maniadakis N, Nagy KV, Parati G, Petronio AS, Pietila M, Prescott E, Ruschitzka F, Van de Werf F, Weidinger F, Zeymer U, Gale CP, Beleslin B, Budaj A, Chioncel O, Dagres N, Danchin N, Emberson J, Erlinge D, Glikson M, Gray A, Kayikcioglu M, Maggioni AP, Nagy KV, Nedoshivin A, Petronio AP, Roos-Hesselink JW, Wallentin L, Zeymer U, Popescu BA, Adlam D, Caforio ALP, Capodanno D, Dweck M, Erlinge D, Glikson M, Hausleiter J, Iung B, Kayikcioglu M, Ludman P, Lund L, Maggioni AP, Matskeplishvili S, Meder B, Nagy KV, Nedoshivin A, Neglia D, Pasquet AA, Roos-Hesselink JW, Rossello FJ, Shaheen SM, Torbica A, Gale CP, Ludman PF, Lettino M, Bueno H, Huber K, Leonardi S, Budaj A, Milasinovic (Serbia) D, Brugaletta S, Appelman Y, Kunadian V, Al Mahmeed WAR, Kzhdryan H, Dumont C, Geppert A, Bajramovic NS, Cader FA, Beauloye C, Quesada D, Hlinomaz O, Liebetrau C, Marandi T, Shokry K, Bueno H, Kovacevic M, Crnomarkovic B, Cankovic M, Dabovic D, Jarakovic M, Pantic T, Trajkovic M, Pupic L, Ruzicic D, Cvetanovic D, Mansourati J, Obradovic I, Stankovic M, Loh PH, Kong W, Poh KK, Sia CH, Saw K, Liška D, Brozmannová D, Gbur M, Gale CP, Maxian R, Kovacic D, Poznic NG, Keric T, Kotnik G, Cercek M, Steblovnik K, Sustersic M, Cercek AC, Djokic I, Maisuradze D, Drnovsek B, Lipar L, Mocilnik M, Pleskovic A, Lainscak M, Crncic D, Nikojajevic I, Tibaut M, Cigut M, Leskovar B, Sinanis T, Furlan T, Grilj V, Rezun M, Mateo VM, Anguita MJF, Bustinza ICM, Quintana RB, Cimadevilla OCF, Fuertes J, Lopez F, Dharma S, Martin MD, Martinez L, Barrabes JA, Bañeras J, Belahnech Y, Ferreira-Gonzalez I, Jordan P, Lidon RM, Mila L, Sambola A, Orvin K, Sionis A, Bragagnini W, Cambra AD, Simon C, Burdeus MV, Ariza-Solé A, Alegre O, Alsina M, Ferrando JIL, Bosch X, Sinha A, Vidal P, Izquierdo M, Marin F, Esteve-Pastor MA, Tello-Montoliu A, Lopez-Garcia C, Rivera-Caravaca JM, Gil-Pérez P, Nicolas-Franco S, Keituqwa I, Farhan HA, Silva L, Blasco A, Escudier JM, Ortega J, Zamorano JL, Sanmartin M, Pereda DC, Rincon LM, Gonzalez P, Casado T, Sadeghipour P, Lopez-Sendon JL, Manjavacas AMI, Marin LAM, Sotelo LR, Rodriguez SOR, Bueno H, Martin R, Maruri R, Moreno G, Moris C, Gudmundsdottir I, Avanzas P, Ayesta A, Junco-Vicente A, Cubero-Gallego H, Pascual I, Sola NB, Rodriguez OA, Malagon L, Martinez-Basterra J, Arizcuren AM, Indolfi C, Romero J, Calleja AG, Fuertes DG, Crespín Crespín M, Bernal FJC, Ojeda FB, Padron AL, Cabeza MM, Vargas CM, Yanes G, Kitai T, Gonzalez MJG, Gonzalez Gonzalez J, Jorge P, De La Fuente B, Bermúdez MG, Perez-Lopez CMB, Basiero AB, Ruiz AC, Pamias RF, Chamero PS, Mirrakhimov E, Hidalgo-Urbano R, Garcia-Rubira JC, Seoane-Garcia T, Arroyo-Monino DF, Ruiz AB, Sanz-Girgas E, Bonet G, Rodríguez-López J, Scardino C, De Sousa D, Gustiene O, Elbasheer E, Humida A, Mahmoud H, Mohamed A, Hamid E, Hussein S, Abdelhameed M, Ali T, Ali Y, Eltayeb M, Philippe F, Ali M, Almubarak E, Badri M, Altaher S, Alla MD, Dellborg M, Dellborg H, Hultsberg-Olsson G, Marjeh YB, Abdin A, Erglis A, Alhussein F, Mgazeel F, Hammami R, Abid L, Bahloul A, Charfeddine S, Ellouze T, Canpolat U, Oksul M, Muderrisoglu H, Popovici M, Karacaglar E, Akgun A, Ari H, Ari S, Can V, Tuncay B, Kaya H, Dursun L, Kalenderoglu K, Tasar O, Kalpak O, Kilic S, Kucukosmanoglu M, Aytekin V, Baydar O, Demirci Y, Gürsoy E, Kilic A, Yildiz Ö, Arat-Ozkan A, Sinan UY, Dagva M, Gungor B, Sekerci SS, Zeren G, Erturk M, Demir AR, Yildirim C, Can C, Kayikcioglu M, Yagmur B, Oney S, Xuereb RG, Sabanoglu C, Inanc IH, Ziyrek M, Sen T, Astarcioglu MA, Kahraman F, Utku O, Celik A, Surmeli AO, Basaran O, Ahmad WAW, Demirbag R, Besli F, Gungoren F, Ingabire P, Mondo C, Ssemanda S, Semu T, Mulla AA, Atos JS, Wajid I, Appelman Y, Al Mahmeed WAR, Atallah B, Bakr K, Garrod R, Makia F, Eldeeb F, Abdekader R, Gomaa A, Kandasamy S, Maruthanayagam R, Nadar SK, Nakad G, Nair R, Mota P, Prior P, Mcdonald S, Rand J, Schumacher N, Abraheem A, Clark M, Coulding M, Qamar N, Turner V, Negahban AQ, Crew A, Hope S, Howson J, Jones S, Lancaster N, Nicholson A, Wray G, Donnelly P, Gierlotka M, Hammond L, Hammond S, Regan S, Watkin R, Papadopoulos C, Ludman P, Hutton K, Macdonald S, Nilsson A, Roberts S, Monteiro S, Garg S, Balachandran K, Mcdonald J, Singh R, Marsden K, Davies K, Desai H, Goddard W, Iqbal N, Chalil S, Dan GA, Galasko G, Assaf O, Benham L, Brown J, Collins S, Fleming C, Glen J, Mitchell M, Preston S, Uttley A, Radovanovic M, Lindsay S, Akhtar N, Atkinson C, Vinod M, Wilson A, Clifford P, Firoozan S, Yashoman M, Bowers N, Chaplin J, Reznik EV, Harvey S, Kononen M, Lopesdesousa G, Saraiva F, Sharma S, Cruddas E, Law J, Young E, Hoye A, Harper P, Balghith M, Rowe K, Been M, Cummins H, French E, Gibson C, Abraham JA, Hobson S, Kay A, Kent M, Wilkinson A, Mohamed A, Clark S, Duncan L, Ahmed IM, Khatiwada D, Mccarrick A, Wanda I, Read P, Afsar A, Rivers V, Theobald T, Cercek M, Bell S, Buckman C, Francis R, Peters G, Stables R, Morgan M, Noorzadeh M, Taylor B, Twiss S, Widdows P, Brozmannová D, Wilkinson V, Black M, Clark A, Clarkson N, Currie J, George L, Mcgee C, Izzat L, Lewis T, Omar Z, Aytekin V, Phillips S, Ahmed F, Mackie S, Oommen A, Phillips H, Sherwood M, Aleti S, Charles T, Jose M, Kolakaluri L, Ingabire P, Karoudi RA, Deery J, Hazelton T, Knight A, Price C, Turney S, Kardos A, Williams F, Wren L, Bega G, Alyavi B, Scaletta D, Kunadian V, Cullen K, Jones S, Kirkup E, Ripley DP, Matthews IG, Mcleod A, Runnett C, Thomas HE, Cartasegna L, Gunarathne A, Burton J, King R, Quinn J, Sobolewska J, Munt S, Porter J, Christenssen V, Leng K, Peachey T, Gomez VN, Temple N, Wells K, Viswanathan G, Taneja A, Cann E, Eglinton C, Hyams B, Jones E, Reed F, Smith J, Beltrano C, Affleck DC, Turner A, Ward T, Wilmshurst N, Stirrup J, Brunton M, Whyte A, Smith S, Murray V, Walker R, Novas V, Weston C, Brown C, Collier D, Curtis K, Dixon K, Wells T, Trim F, Ghosh J, Mavuri M, Barman L, Dumont C, Elliott K, Harrison R, Mallinson J, Neale T, Smith J, Toohie J, Turnbull A, Parker E, Hossain R, Cheeseman M, Balparda H, Hill J, Hood M, Hutchinson D, Mellows K, Pendlebury C, Storey RF, Barker J, Birchall K, Denney H, Housley K, Cardona M, Middle J, Kukreja N, Gati S, Kirk P, Lynch M, Srinivasan M, Szygula J, Baker P, Cruz C, Derigay J, Cigalini C, Lamb K, Nembhard S, Price A, Mamas M, Massey I, Wain J, Delaney J, Junejo S, Martin K, Obaid D, Hoyle V, Brinkworth E, Davies C, Evans D, Richards S, Thomas C, Williams M, Dayer M, Mills H, Roberts K, Goodchild F, Dámaso ES, Greig N, Kundu S, Donaldson D, Tonks L, Beekes M, Button H, Hurford F, Motherwell N, Summers-Wall J, Felmeden D, Tapia V, Keeling P, Sheikh U, Yonis A, Felmeden L, Hughes D, Micklewright L, Summerhayes A, Sutton J, Panoulas V, Prendergast C, Poghosyan K, Rogers P, Barker LN, Batin P, Conway D, Exley D, Fletcher A, Wright J, Nageh T, Hadebe B, Kunhunny S, Mkhitaryan S, Mshengu E, Karthikeyan VJ, Hamdan H, Cooper J, Dandy C, Parkinson V, Paterson P, Reddington S, Taylor T, Tierney C, Adamyan M, Jones KV, Broadley A, Beesley K, Buckley C, Hellyer C, Pippard L, Pitt-Kerby T, Azam J, Hayes C, Freshwater K, Boyadjian S, Johnson L, Mcgill Y, Redfearn H, Russell M, Alyavi A, Alyavi B, Uzokov J, Hayrapetyan H, Azaryan K, Tadevosyan M, Poghosyan H, Kzhdryan H, Vardanyan A, Huber K, Geppert A, Ahmed A, Weidinger F, Derntl M, Hasun M, Schuh-Eiring T, Riegler L, Haq MM, Cader FA, Dewan MAM, Fatema ME, Hasan AS, Islam MM, Khandoker F, Mayedah R, Nizam SU, Azam MG, Arefin MM, Jahan J, Schelfaut D, De Raedt H, Wouters S, Aerts S, Batjoens H, Beauloye C, Dechamps M, Pierard S, Van Caenegem O, Sinnaeve F, Claeys MJ, Snepvangers M, Somers V, Gevaert S, Schaubroek H, Vervaet P, Buysse M, Renders F, Dumoulein M, Hiltrop N, De Coninck M, Naessens S, Senesael I, Hoffer E, Pourbaix S, Beckers J, Dugauquier C, Jacquet S, Malmendier D, Massoz M, Evrard P, Collard L, Brunner P, Carlier S, Blockmans M, Mayne D, Timiras E, Guédès A, Demeure F, Hanet C, Domange J, Jourdan K, Begic E, Custovic F, Dozic A, Hrvat E, Kurbasic I, Mackic D, Subo A, Durak-Nalbantic A, Dzubur A, Rebic D, Hamzic-Mehmedbasic A, Redzepovic A, Djokic-Vejzovic A, Hodzic E, Hujdur M, Musija E, Gljiva-Gogic Z, Serdarevic N, Bajramovic NS, Brigic L, Halilcevic M, Cibo M, Hadžibegic N, Kukavica N, Begic A, Iglica A, Osmanagic A, Resic N, Grgurevic MV, Zvizdic F, Pojskic B, Mujaric E, Selimovic H, Ejubovic M, Pojskic L, Stimjanin E, Sut M, Zapata PS, Munoz CG, Andrade LAF, Upegui MPT, Perez LE, Chavarria J, Quesada D, Alvarado K, Zaputovic L, Tomulic V, Gobic D, Jakljevic T, Lulic D, Bacic G, Bastiancic L, Avraamides P, Eftychiou C, Eteocleous N, Ioannou A, Lambrianidi C, Drakomathioulakis M, Groch L, Hlinomaz O, Rezek M, Semenka J, Sitar J, Beranova M, Kramarikova P, Pesl L, Sindelarova S, Tousek F, Warda HM, Ghaly I, Habiba S, Habib A, Gergis MN, Bahaa H, Samir A, Taha HSE, Adel M, Algamal HM, Mamdouh M, Shaker AF, Shokry K, Konsoah A, Mostafa AM, Ibrahim A, Imam A, Hafez B, Zahran A, Abdelhamid M, Mahmoud K, Mostafa A, Samir A, Abdrabou M, Kamal A, Sallam S, Ali A, Maghraby K, Atta AR, Saad A, Ali M, Lotman EM, Lubi R, Kaljumäe H, Uuetoa T, Kiitam U, Durier C, Ressencourt O, El Din AA, Guiatni A, Bras ML, Mougenot E, Labeque JN, Banos JL, Capendeguy O, Mansourati J, Fofana A, Augagneur M, Bahon L, Pape AL, Batias-Moreau L, Fluttaz A, Good F, Prieur F, Boiffard E, Derien AS, Drapeau I, Roy N, Perret T, Dubreuil O, Ranc S, Rio S, Bonnet JL, Bonnet G, Cuisset T, Deharo P, Mouret JP, Spychaj JC, Blondelon A, Delarche N, Decalf V, Guillard N, Hakme A, Roger MP, Biron Y, Druelles P, Loubeyre C, Lucon A, Hery P, Nejjari M, Digne F, Huchet F, Neykova A, Tzvetkov B, Larrieu M, Quaino G, Armangau P, Sauguet A, Bonfils L, Dumonteil N, Fajadet J, Farah B, Honton B, Monteil B, Philippart R, Tchetche D, Cottin M, Petit F, Piquart A, Popovic B, Varlot J, Maisuradze D, Sagirashvili E, Kereselidze Z, Totladze L, Ginturi T, Lagvilava D, Hamm C, Liebetrau C, Haas M, Hamm C, Koerschgen T, Weferling M, Wolter JS, Maier K, Nickenig G, Sedaghat A, Zachoval C, Lampropoulos K, Mpatsouli A, Sakellaropoulou A, Tyrovolas K, Zibounoumi N, Argyropoulos K, Toulgaridis F, Kolyviras A, Tzanis G, Tzifos V, Milkas A, Papaioannou S, Kyriazopoulos K, Pylarinou V, Kontonassakis I, Kotakos C, Kourgiannidis G, Ntoliou P, Parzakonis N, Pipertzi A, Sakalidis A, Ververeli CL, Kafkala K, Sinanis T, Diakakis G, Grammatikopoulos K, Papoutsaki E, Patialiatos T, Mamaloukaki M, Papadaki ST, Kanellos IE, Antoniou A, Tsinopoulos G, Goudis C, Giannadaki M, Daios S, Petridou M, Skantzis P, Koukis P, Dimitriadis F, Savvidis M, Styliadis I, Sachpekidis V, Pilalidou A, Stamatiadis N, Fotoglidis A, Karakanas A, Ruzsa Z, Becker D, Nowotta F, Gudmundsdottir I, Libungan B, Skuladottir FB, Halldorsdottir H, Shetty R, Iyengar S, Bs C, G S, Lakshmana S, S R, Tripathy N, Sinha A, Choudhary B, Kumar A, Kumar A, Raj R, Roy RS, Dharma S, Siswanto BB, Farhan HA, Yaseen IF, Al-Zaidi M, Dakhil Z, Amen S, Rasool B, Rajeeb A, Amber K, Ali HH, Al-Kinani T, Almyahi MH, Al-Obaidi F, Masoumi G, Sadeghi M, Heshmat-Ghahdarijani K, Roohafza H, Sarrafzadegan N, Shafeie M, Teimouri-Jervekani Z, Noori F, Kyavar M, Sadeghipour P, Firouzi A, Alemzadeh-Ansari MJ, Ghadrdoost B, Golpira R, Ghorbani A, Ahangari F, Salarifar M, Jenab Y, Biria A, Haghighi S, Mansouri P, Yadangi S, Kornowski R, Orvin K, Eisen A, Oginetz N, Vizel R, Kfir H, Pasquale GD, Casella G, Cardelli LS, Filippini E, Zagnoni S, Donazzan L, Ermacora D, Indolfi C, Polimeni A, Curcio A, Mongiardo A, De Rosa S, Sorrentino S, Spaccarotella C, Landolina M, Marino M, Cacucci M, Vailati L, Bernabò P, Montisci R, Meloni L, Marchetti MF, Biddau M, Garau E, Barbato E, Morisco C, Strisciuglio T, Canciello G, Lorenzoni G, Casu G, Merella P, Novo G, D'Agostino A, Di Lisi D, Di Palermo A, Evola S, Immordino F, Rossetto L, Spica G, Pavan D, Mattia AD, Belfiore R, Grandis U, Vendrametto F, Spagnolo C, Carniel L, Sonego E, Gaudio C, Barillà F, Biccire FG, Bruno N, Ferrari I, Paravati V, Torromeo C, Galasso G, Peluso A, Prota C, Radano I, Benvenga RM, Ferraioli D, Anselmi M, Frigo GM, Sinagra G, Merlo M, Perkan A, Ramani F, Altinier A, Fabris E, Rinaldi M, Usmiani T, Checco L, Frea S, Mussida M, Matsukawa R, Sugi K, Kitai T, Furukawa Y, Masumoto A, Miyoshi Y, Nishino S, Assembekov B, Amirov B, Chernokurova Y, Ibragimova F, Mirrakhimov E, Ibraimova A, Murataliev T, Radzhapova Z, Uulu ES, Zhanyshbekova N, Zventsova V, Erglis A, Bondare L, Zaliunas R, Gustiene O, Dirsiene R, Marcinkeviciene J, Sakalyte G, Virbickiene A, Baksyte G, Bardauskiene L, Gelmaniene R, Salkauskaite A, Ziubryte G, Kupstyte-Kristapone N, Badariene J, Balciute S, Kapleriene L, Lizaitis M, Marinskiene J, Navickaite A, Pilkiene A, Ramanauskaite D, Serpytis R, Silinskiene D, Simbelyte T, Staigyte J, Philippe F, Degrell P, Camus E, Ahmad WAW, Kassim ZA, Xuereb RG, Buttigieg LL, Camilleri W, Pllaha E, Xuereb S, Popovici M, Ivanov V, Plugaru A, Moscalu V, Popovici I, Abras M, Ciobanu L, Litvinenco N, Fuior S, Dumanschi C, Ivanov M, Danila T, Grib L, Filimon S, Cardaniuc L, Batrinac A, Tasnic M, Cozma C, Revenco V, Sorici G, Dagva M, Choijiljav G, Dandar E, Khurelbaatar MU, Tsognemekh B, Appelman Y, Den Hartog A, Kolste HJT, Van Den Buijs D, Van'T Hof A, Pustjens T, Houben V, Kasperski I, Ten Berg J, Azzahhafi J, Bor W, Yin DCP, Mbakwem A, Amadi C, Kushimo O, Kilasho M, Oronsaye E, Bakracheski N, Bashuroska EK, Mojsovska V, Tupare S, Dejan M, Jovanoska J, Razmoski D, Marinoski T, Antovski A, Jovanovski Z, Kocho S, Markovski R, Ristovski V, Samir AB, Biserka S, Kalpak O, Peovska IM, Taleska BZ, Pejkov H, Busljetik O, Zimbakov Z, Grueva E, Bojovski I, Tutic M, Poposka L, Vavlukis M, Al-Riyami A, Nadar SK, Abdelmottaleb W, Ahmed S, Mujtaba MS, Al-Mashari S, Al-Riyami H, Laghari AH, Faheem O, Ahmed SW, Qamar N, Furnaz S, Kazmi K, Saghir T, Aneel A, Asim A, Madiha F, Sobkowicz B, Tycinska A, Kazimierczyk E, Szyszkowska A, Mizia-Stec K, Wybraniec M, Bednarek A, Glowacki K, Prokopczuk J, Babinski W, Blachut A, Kosiak M, Kusinska A, Samborski S, Stachura J, Szastok H, Wester A, Bartoszewska D, Sosnowska-Pasiarska B, Krzysiek M, Legutko J, Nawrotek B, Kasprzak JD, Klosinska M, Wiklo K, Kurpesa M, Rechcinski T, Cieslik-Guerra U, Gierlotka M, Bugajski J, Feusette P, Sacha J, Przybylo P, Krzesinski P, Ryczek R, Karasek A, Kazmierczak-Dziuk A, Mielniczuk M, Betkier-Lipinska K, Roik M, Labyk A, Krakowian M, Machowski M, Paczynska M, Potepa M, Pruszczyk P, Budaj A, Ambroziak M, Omelanczuk-Wiech E, Torun A, Opolski G, Glowczynska R, Fojt A, Kowalik R, Huczek Z, Jedrzejczyk S, Roleder T, Brust K, Gasior M, Desperak P, Hawranek M, Farto-Abreu P, Santos M, Baptista S, Brizida L, Faria D, Loureiro J, Magno P, Monteiro C, Nédio M, Tavares J, Sousa C, Almeida I, Almeida S, Miranda H, Santos H, Santos AP, Goncalves L, Monteiro S, Baptista R, Ferreira C, Ferreira J, Goncalves F, Lourenço C, Monteiro P, Picarra B, Santos AR, Guerreiro RA, Carias M, Carrington M, Pais J, de Figueiredo MP, Rocha AR, Mimoso J, De Jesus I, Fernandes R, Guedes J, Mota T, Mendes M, Ferreira J, Tralhão A, Aguiar CT, Strong C, Da Gama FF, Pais G, Timóteo AT, Rosa SAO, Mano T, Reis J, Selas M, Mendes DE, Satendra M, Pinto P, Queirós C, Oliveira I, Reis L, Cruz I, Fernandes R, Torres S, Luz A, Campinas A, Costa R, Frias A, Oliveira M, Martins V, Castilho B, Coelho C, Moura AR, Cotrim N, Dos Santos RC, Custodio P, Duarte R, Gomes R, Matias F, Mendonca C, Neiva J, Rabacal C, Almeida AR, Caeiro D, Queiroz P, Silva G, Pop-Moldovan AL, Darabantiu D, Mercea S, Dan GA, Dan AR, Dobranici M, Popescu RA, Adam C, Sinescu CJ, Andrei CL, Brezeanu R, Samoila N, Baluta MM, Pop D, Tomoaia R, Istratoaie O, Donoiu I, Cojocaru A, Oprita OC, Rocsoreanu A, Grecu M, Ailoaei S, Popescu MI, Cozma A, Babes EE, Rus M, Ardelean A, Larisa R, Moisi M, Ban E, Buzle A, Filimon G, Dobreanu D, Lupu S, Mitre A, Rudzik R, Sus I, Opris D, Somkereki C, Mornos C, Petrescu L, Betiu A, Volcescu A, Ioan O, Luca C, Maximov D, Mosteoru S, Pascalau L, Roman C, Brie D, Crisan S, Erimescu C, Falnita L, Gaita D, Gheorghiu M, Levashov S, Redkina M, Novitskii N, Dementiev E, Baglikov A, Zateyshchikov D, Zubova E, Rogozhina A, Salikov A, Nikitin I, Reznik EV, Komissarova MS, Shebzukhova M, Shitaya K, Stolbova S, Larina V, Akhmatova F, Chuvarayan G, Arefyev MN, Averkov OV, Volkova AL, Sepkhanyan MS, Vecherko VI, Meray I, Babaeva L, Goreva L, Pisaryuk A, Potapov P, Teterina M, Ageev F, Silvestrova G, Fedulaev Y, Pinchuk T, Staroverov I, Kalimullin D, Sukhinina T, Zhukova N, Ryabov V, Kruchinkina E, Vorobeva D, Shevchenko I, Budyak V, Elistratova O, Fetisova E, Islamov R, Ponomareva E, Khalaf H, Shaimaa AA, Kamal W, Alrahimi J, Elshiekh A, Balghith M, Ahmed A, Attia N, Jamiel AA, Potpara T, Marinkovic M, Mihajlovic M, Mujovic N, Kocijancic A, Mijatovic Z, Radovanovic M, Matic D, Milosevic A, Savic L, Subotic I, Uscumlic A, Zlatic N, Antonijevic J, Vesic O, Vucic R, Martinovic SS, Kostic T, Atanaskovic V, Mitic V, Stanojevic D, Petrovic M. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry. Eur Heart J Qual Care Clin Outcomes 2022; 9:8-15. [PMID: 36259751 DOI: 10.1093/ehjqcco/qcac067] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 10/11/2022] [Indexed: 11/12/2022]
Abstract
AIMS The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. METHODS AND RESULTS Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (in-hospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, pre-hospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. CONCLUSION The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality.
Collapse
Affiliation(s)
- Ramesh Nadarajah
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | - Peter Ludman
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Yolande Appelman
- Department of Cardiology, Amsterdam UMC-Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Salvatore Brugaletta
- Hospital Clinic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Andrzej Budaj
- Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
| | - Hector Bueno
- Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.,Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | - Kurt Huber
- 3rd Medical Department, Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), Vienna, Austria.,Medical Faculty, Sigmund Freud University, Vienna, Austria
| | - Vijay Kunadian
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.,Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Sergio Leonardi
- University of Pavia, Pavia, Italy.,Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy
| | - Maddalena Lettino
- Cardio-Thoracic and Vascular Department, San Gerardo Hospital, ASST-Monza, Monza, Italy
| | - Dejan Milasinovic
- Department of Cardiology, University Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Chris P Gale
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Monteiro E, Barbosa J, Guimaraes J, Fernandes D, Costa G, Gomes R, Rosa J, Campos G, Baptista R, Monteiro P, Monteiro S, Goncalves F, Madeira M, Goncalves L. Comparing the long-term prognosis of myocardial infarction with non-obstructive coronary arteries to myocardial infarction with obstructive coronary artery disease. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The long-term survival rates of myocardial infarction with non-obstructive coronary arteries (MINOCA) patients is lower than in the general population. Nevertheless, there are conflicting results regarding the prognosis of MINOCA patients in comparison to myocardial infarction with obstructive coronary artery disease (MI-CAD) patients.
Purpose
The aim of this study was to assess the long-term all-cause mortality of MINOCA patients and compare it to MI-CAD patients.
Methods
Retrospective analysis of 2443 consecutively admitted patients for acute myocardial infarction (AMI), in a single coronary intensive care unit. Only patients with 5 years of follow-up and those who died before the 5-year mark were considered. Patients were divided into two groups according to the presence or absence of obstructive coronary artery disease on angiography (≥50% stenosis). Demographic characteristics, symptoms at presentation, past medical history, laboratory characteristics and medication at discharge were compared using the Mann-Whitney U or χ2 test (according to variable type) to ensure comparability between groups. Five-year all-cause mortality was the target endpoint. Five-year survival was modelled through the Cox proportional hazard regression model. The variable of interest (MINOCA vs MI-CAD) and possible confounders that displayed statistically significant differences in the initial demographic analysis were included in univariable Cox regressions, and those with statistically significant associations were included in a multivariable model. Those that displayed non-significant associations in the multivariable model were subsequently removed until we were left with significant associations only, giving us an adjusted hazard ratio.
Results
Comparison between groups is presented in table 1. MINOCA patients were younger and more often women. They were less likely to have smoking habits, diabetes, or a previous history of AMI. They had a lower Killip class, as well as lower troponin I, serum creatinine and low-density lipoprotein cholesterol at admission. On the other hand, they had higher left ventricular ejection fractions. They were also less likely to have beta-blockers or aspirin prescribed at discharge.
All-cause mortality at 5 years was 13.1% among MINOCA patients and 28.3% among MI-CAD patients, with an unadjusted hazard ratio (HR) of 0.421 (95% CI 0.322–0.550), p<0.001. Adjusting for known confounders, the HR was 0.461 (95% CI 0.261–0.816), p=0.008.
Conclusions
Compared with MI-CAD patients, those with MINOCA were slightly younger and had fewer comorbidities. In spite of having a worse long-term prognosis when compared to the general population, MINOCA patients have a significantly higher 5-year survival rate than MI-CAD patients, even after adjustment of confounding factors.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- E Monteiro
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - J Barbosa
- Faculty of Medicine University of Porto , Porto , Portugal
| | - J Guimaraes
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - D Fernandes
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - G Costa
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - R Gomes
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - J Rosa
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - G Campos
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - R Baptista
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - P Monteiro
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - S Monteiro
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - F Goncalves
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - M Madeira
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| | - L Goncalves
- Centro Hospitalar E Universitario De Coimbra , Coimbra , Portugal
| |
Collapse
|
3
|
Andrade JP, Monteiro P, Prata A, Robl A, Neto J, Dias JR, Pimenta C, Lippe B, Guimarães A, Ribeiro H, Merhi S, Hartmman D, Sartori R, Wiltbank M. 126 ReBreed21, a rapid reinsemination program: fertility in Bos indicus cattle of different parities. Reprod Fertil Dev 2021; 34:300-301. [PMID: 35231264 DOI: 10.1071/rdv34n2ab126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- J P Andrade
- University of Wisconsin-Madison, Madison, WI, USA
| | - P Monteiro
- University of Wisconsin-Madison, Madison, WI, USA
| | - A Prata
- GlobalGen Vet Science, Jaboticabal, SP, Brazil
| | - A Robl
- Agropecuária Roncador, Querência, MT, Brazil
| | - J Neto
- Agropecuária Roncador, Querência, MT, Brazil
| | - J R Dias
- Agropecuária Roncador, Querência, MT, Brazil
| | - C Pimenta
- Agropecuária Roncador, Querência, MT, Brazil
| | - B Lippe
- University of São Paulo, Piracicaba, SP, Brazil
| | - A Guimarães
- University of São Paulo, Piracicaba, SP, Brazil
| | - H Ribeiro
- Agropecuária Roncador, Querência, MT, Brazil
| | - S Merhi
- Agropecuária Roncador, Querência, MT, Brazil
| | - D Hartmman
- Agropecuária Roncador, Querência, MT, Brazil
| | - R Sartori
- University of São Paulo, Piracicaba, SP, Brazil
| | - M Wiltbank
- University of Wisconsin-Madison, Madison, WI, USA
| |
Collapse
|
4
|
De Caterina R, De Groot J, Weiss T, Kelly P, Monteiro P, Deharo J, De Asmundis C, Lopez-De-Sa E, Waltenberger J, Steffel J, Levy P, Bakhai A, Pecen L, Kirchhof P. Age-adjusted risk factors are independently associated with an increased risk of ischaemic stroke, transient ischaemic stroke and systemic embolism in the ETNA-AF-Europe registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Oral anticoagulation is highly effective in preventing ischaemic stroke in patients with atrial fibrillation, but 1–2% of the patients suffer an ischaemic stroke upon anticoagulation. Outcomes are further influenced by various factors, and recent research has focussed on identifying risk factors that could be helpful in predicting stroke outcomes in anticoagulated patients. This could further assist clinicians in timely identification and management of high-risk patients.
Purpose
The present analysis aims to assess the age-adjusted risk predictors of ischaemic stroke and systemic embolic events (SEE) (including transient ischaemic attack [TIA]) during two-year follow-up of unselected European patients with AF in the ETNA-AF-Europe registry.
Methods
ETNA-AF-Europe is a prospective, multi-centre, post-authorisation, observational study conducted in 825 centres enrolling patients treated with edoxaban once daily in 10 European countries. Wald Chi square tested the association between risk predictors and stroke and SEE after adjusting for age, given that age is a well-known, strong predictor of stroke.
Results
A total of 13,417 patients with AF (edoxaban 60 mg: n=10,248; edoxaban 30 mg: n=3169) completed the two-year follow-up. The mean age was 73.6±9.5 years, with ∼84% of the patients aged over 65 years. The mean weight was 81.0±17.3 kg, estimated glomerular filtration rate was 74.4±30.5 ml/min/1.73m2 and males were 56.6%. The mean CHA2DS2-VASc and HAS-BLED scores were 3.2 and 2.5, respectively.
Univariate analysis demonstrated that history of TIA at baseline was the strongest age-adjusted predictor of stroke and SEE (Wald Chi-square: 77.69; p<0.0001) (Figure 1), followed by CHA2DS2-VASc score (41.09; p<0.0001) (Figure 2), history of ischaemic stroke (29.47; p<0.0001), history of any stroke (all strokes combined including stroke of unknown/unspecified type) (29.18; p<0.0001), subjective frailty as assessed by physician (20.60; p<0.0001), and HAS-BLED score (17.22; p<0.0001).
Conclusion
History of TIA, CHA2DS2-VASc score, history of stroke, frailty and HAS-BLED score are independently associated with an increased age-adjusted risk of ischaemic stroke, TIA and SEE in anticoagulated patients with AF. These findings highlight the importance of optimising anticoagulation therapy in secondary prevention of TIA and in patients with high CHA2DS2-VASc scores, ensuring the correct use of NOACs - adherence and correct dosing - in this high-risk population. These findings also suggest that additional therapies could be needed to prevent stroke in this population.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Europe GmbH Figure 1. History of TIA as a predictorFigure 2. CHA2DS2-VASc score as a predictor
Collapse
Affiliation(s)
- R De Caterina
- University of Pisa, Chair of Cardiology, Pisa, Italy
| | - J.R De Groot
- Amsterdam UMC - Location Academic Medical Center, Department of Cardiology, Amsterdam, Netherlands (The)
| | - T.W Weiss
- Karl Landsteiner Institute, Institute for Cardiometabolic Diseases, St. Polten, Austria
| | - P Kelly
- University College Dublin, Department of Neurology, HRB Stroke Clinical Trials Network Ireland, Dublin, Ireland
| | - P Monteiro
- Centro Hospitalar e Universitario de Coimbra, Department of Cardiology, Coimbra, Portugal
| | - J.C Deharo
- AP-HM, Aix Marseille University, Hospital Timone, Cardiologie, Rythmologie, Marseille, France
| | - C De Asmundis
- Universitair Ziekenhuis Brussels, Department of Cardiology, Brussels, Belgium
| | - E Lopez-De-Sa
- Hospital Universitario La Paz, IDIPAZ, CIBERCV, Cardiological Intensive Care Unit, Cardiology Service, Madrid, Spain
| | - J Waltenberger
- University of Munster, Department of Cardiovascular Medicine, Munster, Germany
| | - J Steffel
- University Hospital Zurich, Department of Cardiology, Zurich, Switzerland
| | - P Levy
- Universite Paris-Dauphine, PSL Research University, LEDa-LEGOS, Department of Economics, Paris, France
| | - A Bakhai
- Royal Free London NHS Foundation Trust, Department of Cardiology, London, United Kingdom
| | - L Pecen
- Institute of Computer Science of the Czech Academy of Science, the Czech Academy of Science, Prague, Czechia
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | | |
Collapse
|
5
|
Kirchhof P, De Groot J, Weiss T, Kelly P, Monteiro P, Deharo J, De Asmundis C, Lopez-De-Sa E, Waltenberger J, Steffel J, Levy P, Bakhai A, Pecen L, De Caterina R. Age-adjusted risk factors are independently associated with an increased risk of major bleeding during the two-year follow-up of the ETNA-AF-Europe registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Non-vitamin K antagonist oral anticoagulants (NOACs) are a preferred treatment option over warfarin for anticoagulation in patients with atrial fibrillation (AF). Management decisions for thromboprophylaxis in AF need to balance the risk of stroke against the risk of bleeding. Various patient characteristics have been identified as independent risk factors for bleeding. A substantial number of bleeding events might be prevented if independent predictors of bleeding were identified.
Purpose
The present analysis aims at assessing age-adjusted risk predictors of major bleeding during two-year follow-up of unselected European patients with AF in the ETNA-AF-Europe registry.
Methods
ETNA-AF-Europe is a prospective, multi-centre, post-authorisation, observational study conducted in 825 centres enrolling patients treated with edoxaban once daily in 10 European countries. Wald Chi square tested the association between risk predictors and major bleeding after adjusting for age, given that age is a well-known, strong predictor of anticoagulation-related bleeding in patients with AF.
Results
Overall, 13,417 patients with AF (edoxaban 60 mg: n=10,248; edoxaban 30 mg: n=3169) completed the two-year follow-up. The mean age was 73.6±9.5 years, with ∼84% of the patients aged over 65 years. Mean CHA2DS2-VASc and HAS-BLED scores were 3.2 and 2.5, respectively. 438 (3.3%) patients had a history of bleeding events at baseline, of which 138 (1.0%) had a history of major bleeding event.
Univariate analysis demonstrated that recalculated glomerular filtration rate (Cockcroft-Gault Equation) (GFR-CG) at baseline was the strongest age-adjusted predictor of major bleeding (Wald Chi-Square: 31.84; p<0.0001) (Figures 1 and 2), followed by history of major or clinically relevant non-major (CRNM) bleeding (24.08; p<0.0001), HAS-BLED score (21.10; p<0.0001), history of heart failure (derived) (16.59; p<0.0001), subjective frailty as assessed by physician (17.35; p=0.0002), history of major bleeding (14.14; p=0.0002), chronic obstructive pulmonary disease (COPD) (12.84; p=0.0003), CHA2DS2-VASc (12.14; p=0.0005), history of myocardial infarction (MI) (7.79; p=0.005), and left ventricular ejection fraction (LVEF) categorised by 40% (5.45; p=0.02).
Conclusion
Bleeding events on therapy with edoxaban can be predicted by quantifying kidney disease and capturing information on heart failure, frailty, prior bleeding, chronic obstructive lung disease and history of myocardial infarction. These data highlight the need for optimal management of anticoagulation therapy and close follow-up of patients with such risk profiles.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Europe GmbH Figure 1. GFR-CG as a predictor of major bleedingFigure 2. Predictors of major bleeding
Collapse
Affiliation(s)
- P Kirchhof
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - J.R De Groot
- Amsterdam UMC - Location Academic Medical Center, Department of Cardiology, Amsterdam, Netherlands (The)
| | - T.W Weiss
- Karl Landsteiner Institute, Institute for Cardiometabolic Diseases, St. Polten, Austria
| | - P Kelly
- University College Dublin, Department of Neurology, HRB Stroke Clinical Trials Network Ireland, Dublin, Ireland
| | - P Monteiro
- Centro Hospitalar e Universitario de Coimbra, Department of Cardiology, Coimbra, Portugal
| | - J.C Deharo
- AP-HM, Aix Marseille University, Hospital Timone, Cardiologie, Rythmologie, Marseille, France
| | - C De Asmundis
- Universitair Ziekenhuis, Department of Cardiology, Brussels, Belgium
| | - E Lopez-De-Sa
- Hospital Universitario La Paz, IDIPAZ, CIBERCV, Cardiological Intensive Care Unit, Cardiology Service, Madrid, Spain
| | - J Waltenberger
- University of Munster, Department of Cardiovascular Medicine, Munster, Germany
| | - J Steffel
- University Hospital Zurich, Department of Cardiology, Zurich, Switzerland
| | - P Levy
- Universite Paris-Dauphine, PSL Research University, LEDa-LEGOS, Department of Economics, Paris, France
| | - A Bakhai
- Royal Free London NHS Foundation Trust, Department of Cardiology, London, United Kingdom
| | - L Pecen
- Institute of Computer Science of the Czech Academy of Science, the Czech Academy of Science, Prague, Czechia
| | - R De Caterina
- University of Pisa, Chair of Cardiology, Pisa, Italy
| | | |
Collapse
|
6
|
De Caterina R, De Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, De Asmundis C, Lopez-De-Sa E, Waltenberger J, Steffel J, Levy P, Bakhai A, Kirchhof P. Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study. Europace 2021. [DOI: 10.1093/europace/euab116.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Europe
OnBehalf
ETNA-AF-Europe investigators
Background
Oral anticoagulation (OAC) for stroke prevention is essential in the management of patients with atrial fibrillation (AF). The assessment of OAC use in routine clinical care and the effects of this therapy on outcomes and safety are important. Purpose: We analysed two-year outcome data with adjudicated follow-up results in 13,417 patients with AF treated with edoxaban. Methods: ETNA-AF-Europe (Clinicaltrials.gov: NCT02944019) enrolled 13,417 consecutive patients with AF treated with edoxaban in 825 centres in 10 European countries and 2-year prospectively collected, real world data is presented. Results: Edoxaban was prescribed according to licence recommendations in 83.1% (n = 11,146) of patients (Table). Whilst three quarters of patients were prescribed edoxaban 60 mg (n = 10,248, 76.4%), the quarter prescribed edoxaban 30 mg were older (79.5 versus 71.8 years), had a higher stroke risk (CHA2DS2-VASc score: 3.9 versus 3.0) and a higher bleeding risk (HAS-BLED score: 2.9 versus 2.4). Thromboembolic and bleeding events were more common in patients receiving edoxaban 30 mg OD without differences in intracranial haemorrhage (ICH) (Figure). Patients prescribed a non-recommended dose of edoxaban had a numerically higher stroke risk (CHA2DS2-VASc score: 3.6 versus 3.1) with subsequent higher rates of ischemic stroke and mortality, however they also had higher bleeding rates, with the exception of ICH (table) despite a similar initial bleeding risk (HAS-BLED score: 2.7 versus 2.5). Conclusions: In this large, European data set reporting two-year outcomes on edoxaban therapy, no additional safety signals were observed and event rates were in line with those observed in ETNA-AF after 1 year and in ENGAGE AF-TIMI 48, re-affirming the safety and effectiveness of edoxaban licence recommendations in a real world setting of patients with AF. All key events of interest, other than intracranial haemorrhage, were numerically lower in patients prescribed the licenced recommended dose. Outcomes with rec. vs non-rec. dosesn (%/year [95%CI])Recommended dose (n = 11,146; 83.1%)Non-recommended dose (n = 2271; 16.9%)Any stroke/SEE138 (0.68 [0.57;0.80])31 (0.76 [0.51;1.07])Ischaemic stroke99 (0.48 [0.39;0.59])26 (0.63 [0.41; 0.93])Major bleeding189 (0.93 [0.80;1.07])49 (1.20 [0.89;1.59])Intracranial haemorrhage43 (0.21 [0.15;0.28])7 (0.17 [0.07;0.35])All-cause mortality729 (3.55 [3.30;3.82])208 (5.04 [4.38;5.78])CV mortality405 (1.97 [1.79;2.18])113 (2.74 [2.26;3.30])CI, confidence interval; CV, cardiovascular; rec., recommended; SEE, systemic embolic event.Abstract Figure. Annualised event rates at 2-year FU
Collapse
Affiliation(s)
| | - JR De Groot
- Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands (The)
| | - TW Weiss
- Karl Landsteiner Institute for Cardiometabolics and SFU, Vienna, Austria
| | - P Kelly
- HRB Stroke Clinical Trials Network Ireland, University College Dublin, Dublin, Ireland
| | - P Monteiro
- Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - JC Deharo
- Hôpital de la Timone, Marseille, France
| | | | - E Lopez-De-Sa
- Hospital Universitario La Paz, IDIPAZ, Madrid, Spain
| | - J Waltenberger
- University of Munster and SRH Central Hospital Suhl, Munster, Germany
| | - J Steffel
- University Hospital Zurich, Zurich, Switzerland
| | - P Levy
- Université Paris-Dauphine, PSL Research University, Paris, France
| | - A Bakhai
- Royal Free London NHS Foundation Trust, Barnet Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
7
|
Borges-Rosa J, Campos GM, Martinho S, Almeida JL, Goncalves V, Ferreira C, Freitas AA, Milner J, Ferreira JA, Monteiro S, Goncalves F, Monteiro P, Baptista R, Oliveira-Santos M, Goncalves L. Myocardial infarction in young adults: are the risk profile and mortality outcomes different from older patients? Eur J Prev Cardiol 2021. [DOI: 10.1093/eurjpc/zwab061.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
The incidence of acute myocardial infarction (AMI) among young patients is increasing. The YOUNG-MI Registry reported that those under 40 years had similar risk profiles and outcomes compared to those aged 41 to 50. We aimed to evaluate cardiovascular risk factors and mortality outcomes in two age cohorts from southern European.
Methods
We retrospectively evaluated 4758 patients admitted to our coronary intensive care unit between 2004 and 2017 with AMI. We only included patients <60 years in two subgroups: cohort A < 50 years and cohort B 50-60 years.
Results
From the 1233 patients included (mean age 50.5 ± 6.5 years, 82.2% male), 53% had STEMI. Cohort B had higher rates of hypertension (59.8 vs. 42.9%, p < 0.001), diabetes (41.8 vs. 28.9%, p < 0.001), and dyslipidemia (59.4 vs. 46.4%, p < 0.001), while cohort A had higher rates of familial premature coronary artery disease (20.9 vs. 13.2%, p < 0.001) and smoking habits (54.4 vs. 40.0%, p < 0.001). Regarding coronary angiography, cohort B had higher rates of obstructive disease in each epicardial artery, except for left main involvement and non-obstructive disease (Fig. 1). Cohort A had lower all-cause mortality rates at the index hospitalization (1.3 vs. 3.2%, p = 0.045), 6-months (2.9 vs.5.4, p = 0.038), 1-year (3.1 vs. 6.3%, p = 0.014), and 3-years (3.6 vs 8.4, p = 0.001). After multivariable adjustment, we found no relationship between age cohorts and all-cause mortality for any follow-up timing: HR 1.57 (95% CI 0.56-4.37), 1.37 (95% CI 0.50-3.74), and 0.92 (95% CI 0.35-2.39) at 6-months, 1-year, and 3-years, respectively.
Conclusion
Among patients who suffer AMI, those under 50 years old have a different risk profile, compared to the 50-60 years cohort. However, there is no significant difference in all-cause mortality.
Abstract Figure.
Collapse
Affiliation(s)
| | - GM Campos
- University Hospitals of Coimbra, Coimbra, Portugal
| | - S Martinho
- University Hospitals of Coimbra, Coimbra, Portugal
| | - JL Almeida
- University Hospitals of Coimbra, Coimbra, Portugal
| | - V Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| | - C Ferreira
- University Hospitals of Coimbra, Coimbra, Portugal
| | - AA Freitas
- University Hospitals of Coimbra, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Coimbra, Portugal
| | - JA Ferreira
- University Hospitals of Coimbra, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Coimbra, Portugal
| | - F Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Coimbra, Portugal
| | - R Baptista
- University Hospitals of Coimbra, Coimbra, Portugal
| | | | - L Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| |
Collapse
|
8
|
De Caterina R, Gwechenberger M, Bakhai A, Monteiro P, Kelly P, Levy P, Kirchhof P. Baseline characteristics and follow-up outcomes in routine clinical practice patients categorised by renal function in the ETNA-AF-Europe registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Edoxaban is an oral factor Xa inhibitor anticoagulant with 50% renal clearance, and proven efficacy and safety in patients (pts) with atrial fibrillation (AF). The post-authorisation, observational, ETNA-AF-Europe registry (NCT02944019) assessed the risks and benefits of edoxaban in pts with AF from 10 European countries.
Purpose
Evaluate baseline characteristics and event rates in pts categorised by creatinine clearance (CrCl) at 1-year follow-up of the ETNA-AF-Europe registry.
Methods
In this analysis, pts were divided into three groups according to CrCl: ≤50 ml/min (I), 50–80 mL/min (II) and ≥80 mL/min (III) (calculated using Cockcroft-Gault). Outcomes were descriptively analysed.
Results
Pts with the lowest CrCl (Group I) were mostly females, and had a higher mean age, lower body weight, higher stroke and bleeding risk scores and were considered more frail than those with higher CrCl (Groups II and III) (Table). Group I experienced higher rates of stroke or SEE, major or CRNM bleeding, cardiovascular death, and had a higher total mortality (Figure). Rates of intracranial haemorrhage (ICH) and haemorrhagic stroke (intracerebral and subarachnoid haemorrhage) were low and similar in pts across the range of CrCl.
Conclusions
Those with lower CrCl had more comorbidities and higher event rates than those with higher CrCl, with the exception of ICH and haemorrhagic stroke. A steep rise in the proportion of pts perceived as frail and in overall mortality in the lowest renal function tertile, raises the question whether low renal function is a determinant or a correlate of mortality.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Daiichi Sankyo Europe GmbH, Munich, Germany
Collapse
Affiliation(s)
| | | | - A Bakhai
- Royal Free London NHS Foundation Trust, Barnet Hospital, London, United Kingdom
| | - P Monteiro
- Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - P Kelly
- University College Dublin, HRB Stroke Clinical Trials Network Ireland, Dublin, Ireland
| | - P Levy
- Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands (The)
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
9
|
Ferreira C, Baptista R, Ribeiro A, Freitas A, Ferreira J, Milner J, Martinho A, Almeida J, Goncalves V, Campos G, Rosa J, Goncalves F, Monteiro S, Monteiro P, Goncalves L. Inequalities after STEMI in National Health Service: is there really a postcode lottery? Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background and purpose
Failure to address the impact of social determinants of health attenuates efficacy of proven prevention recommendations, namely because important considerations related to socioeconomic disadvantage are not captured by existing cardiovascular disease (CDV) risk stratification methods. We aimed to assess how socioeconomic determinants influence recurrent MI and all-cause death after myocardial infarction (MI) in Portugal.
Methods
We conducted a retrospective, observational cohort study, including all patients with a ST-elevation MI (STEMI) admitted to and discharged alive from an intensive cardiac care unit between 2004 and 2017 (n=1809). The median (interquartile range) follow-up was 6 (4–9) years. We used survival models to assess the relationship between their municipal (i) income by purchasing power per capita (PPC), (ii) geographical accessibility to health care, (iii) illiteracy, iv) residential socioeconomic deprivation and recurrent MI and all-cause mortality. To assess residential socioeconomic deprivation, each individual's residential postcode was matched to the recently validated Portuguese version of European Deprivation Index (EDI). The index was categorized into quintiles (Q1-least deprived to Q5-most deprived).
Results
The mean age was 64±14 years; 74% were male. Regarding individual socioeconomic variables, PPC (HR 1.19; 95% CI 0.97–1.47 for Tertile 1 vs Tertile 2; HR 1.28; 95% CI 1.04–1.56 for Tertile 1 vs Tertile 3 and HR 1.07; 95% CI 0.85–1.34 for Tertile 2 vs Tertile 3) and medical appointments in primary health centers per inhabitant (HR 0.90; 95% CI 0.75–1.09 for Tertile 1 vs Tertile 2; HR 1.23; 95% CI 0.95–1.61 for Tertile 1 vs Tertile 3 and HR 1.37; 95% CI 1.06–1.76 for Tertile 2 vs Tertile 3) were predictors of all-cause mortality, but not recurrent MI; however, in multivariate analysis adjusted for sex, age and ejection fraction, this association was no longer significant (HR 1.00; 95% CI 0.99–1.00 and, HR 1.00; 95% CI 0.89–1.17, respectively). Additionally, no evident association between illiteracy and all-cause mortality or MI was present. Concerning EDI, demographic data was similar among the quintiles (Table 1). Although EDI quintiles were not associated with all-cause mortality (HR 1.17; 95% CI 0.82–1.66 for Q5 vs Q1), the EDI was an independent predictor of recurrent MI (Figure 1). On multivariate analysis, adjusted for age, sex, hypertension, diabetes and LDL cholesterol, the HR for the most deprived (Q5) to the least deprived (Q1) quintile was 1.91 (95% CI 1.05–3.49) for MI.
Conclusions
Our study shows clear socioeconomic differentials in cardiovascular outcomes in patients with STEMI which suggests that accounting for socioeconomic deprivation might improve risk prediction and therefore disease prognosis.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- C Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - R Baptista
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - A.I Ribeiro
- University of Porto, Public Health Institute, Porto, Portugal
| | - A Freitas
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J.A Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - A Martinho
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J.P Almeida
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - V Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - G Campos
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J Rosa
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - F Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - L Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| |
Collapse
|
10
|
Cordero A, Cid B, Monteiro P, Garcia-Acuna J, Rodriguez-Manero M, Trillo Noche R, Lopez Otero D, Sanmartin Pena J, Bertomeu-Gonzalez V, Escribano D, Goncalvez F, Goncalves L, Zuazola P, Gonzalez-Juanatey J. Validation of the Zwolle score for selection of very low-risk STEMI patients treated with primary angioplasty. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The Zwolle risk score was designed to stratify the actual in-hospital mortality risk of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (p-PCI) but, also, for decision-making related to patients location in an intensive care unit or not. Since the GRACE score continues being the gold-standard for individual risk assessment in STEMI in most institutions we assessed the specificity of both scores for in-hospital mortality.
Methods
We assessed the accuracy of Zwolle risk score for in-hospital mortality estimation as compared to the GRACE score in all patients admitted for STEMI in 3 tertitary hospitals. Patients with Zwolle risk score <3 would qualify as “low risk”, 3–5 as “intermediate risk” and ≥6 as “high risk”. Patients with GRACE score <140 were classified as low-risk. Specificity, sensitivity and classification were assessed by ROC curves and the area under the curve (AUC).
Results
We included 4,446 patients, mean age 64.7 (13.6) years, 24% women and 39% with diabetes. Mean GRACE score was 157.3 (4.9) and Zwolle was 2.8 (3.3). In-hospital mortality was 10.6% (471 patients). Patients who died had higher GRACE score (218.4±4.9 vs. 149.6±37.5; p<0.001) and Zwolle score (7.6±4.3 vs. 2.3±2.18; p<0.001); a statistically significant increase of in-hospital mortality risk, adjusted adjusted by age, gender and revascularization, was observed with both scores (figure). A total of 1,629 patients (40.0%) were classified as low risk by the GRACE score and 2,962 (66.6%) by the Zwolle score; in-hospital mortality was 1.6% and 2.7%, respectively. Moreover, the was a significant increase of in-hospital mortality rate according to Zwolle categories (2.7%; 13.0%; 41.6%)The AUC of both score was the same (p=0.49) but the specificity of GRACE score <140 was 43.1% as compared to 72.6% obtained by Zwolle score <3; patients accurately classified was also lower with the GRACE score threshold (48.8% vs. 73.7%).
Conclusions
Selection of low-risk STEMI patients treated with p-PCI based on the Zwolle risk score has higher specificity than the GRACE score and might be useful for the care organization in clinical practice.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- A Cordero
- University Hospital of San Juan, Alicante, Spain
| | - B Cid
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J.M Garcia-Acuna
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - M Rodriguez-Manero
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - R Trillo Noche
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - D Lopez Otero
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - J.C Sanmartin Pena
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | | | - D Escribano
- University Hospital of San Juan, Alicante, Spain
| | - F Goncalvez
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - L Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Zuazola
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - J.R Gonzalez-Juanatey
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| |
Collapse
|
11
|
Borges-Rosa J, Ferreira J, Oliveira-Santos M, Monteiro S, Goncalves F, Monteiro P, Baptista R, Goncalves L. A real world analysis of NSTE-ACS in more than 4000 patients: accuracy of GRACE and TIMI scores in mortality prediction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Introduction
The TIMI (Thrombolysis in Myocardial Infarction) and GRACE (Global Registry of Acute Coronary Events) risk scores identify high-risk patients with Non-ST elevation acute coronary syndrome (NSTE-ACS) who can benefit from an early invasive strategy.
Purpose
We aimed to compare both scores predictive accuracy for mortality in a real-world cohort of patients presenting with NSTE-ACS.
Methods
We retrospectively evaluated 4264 patients admitted to our coronary intensive care unit between 2004 and 2017 with a diagnosis of NSTE-ACS. The TIMI and GRACE scores were calculated for each patient, and all-cause mortality was recorded during hospitalization, at one month and one year. To better characterize global troponin release, we defined Total Troponin (TT) as the sum of initial and discharge troponin. We used the area under the receiver operating characteristic curve (AUC) to compare the predictive value of both scores for mortality during hospitalization, at one month and one year.
Results
Mean patient age was 67.6±12.4 years and 66.4% were male (n=2833). Mean GRACE score was 124.6±35.8 and mean TIMI score was 2.7±1.6. There was a weak correlation between GRACE and TIMI score (r=0.3, p<0.001). In-hospital mortality was 2.8%: the GRACE score showed higher AUC (0.845, 95% CI 0.805–0.804, p<0.001) compared to TIMI (0.581, 95% CI 0.519–0.643, p=0.009) (Figure 1). Mortality at one month was 5.1%: the GRACE score showed higher AUC (0.842, 95% CI 0.814–0.869, p<0.001) compared to TIMI (0.586, 95% CI 0.541–0.630, p<0.001). Mortality at one year was 11.4%: the GRACE score showed higher AUC (0.811, 95% CI 0.789–0.822, p<0.001) compared to TIMI (0.591, 95% CI 0.560–0.622, p<0.001) (Fig. 1). Analyzing Unstable Angina and Non-ST segment elevation myocardial infarction separately, the GRACE score also showed higher AUC compared to TIMI. Exploratory analyses revealed a combined indicator (GRACE score + TT) which had higher AUC (0.876, 95% CI 0.844–0.907, p<0.001) compared to GRACE score (0.855, 95% CI 0.823–0.887, p<0.001) for one month mortality and for one year mortality (0.818, 95% CI 0.792–0.844, p<0.001 vs. 0.813, 95% CI 0.788–0.839, p<0.001).
Conclusion
In patients with NSTE-ACS, GRACE risk score is a better predictor of in-hospital, one month and one-year mortality, compared to TIMI risk score. TT, as a measure of ischemia burden, might improve accuracy of GRACE score in predicting short and long-term mortality.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - J Ferreira
- University Hospitals of Coimbra, Coimbra, Portugal
| | | | - S Monteiro
- University Hospitals of Coimbra, Coimbra, Portugal
| | - F Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Coimbra, Portugal
| | - R Baptista
- University Hospitals of Coimbra, Coimbra, Portugal
| | - L Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| |
Collapse
|
12
|
Barreira SC, Cruz-Machado AR, Fernandes AL, Genrinho I, Sequeira G, Monteiro P, Fonseca JE. AB1145 PRESCRIPTION PATTERNS AND DISEASE ACTIVITY IN PORTUGUESE WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND JUVENILE IDIOPATHIC ARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Disease activity (DA) at conception is one of the main predictors of pregnancy outcomes in women of childbearing age (WoCBA) with rheumatic diseases. Teratogenicity and unawareness about pregnancy compatibility of some disease-modifying anti-rheumatic drugs might limit the choice of treatment in WoCBA.Objectives:To assess differences in prescription patterns between WoCBA with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA) and comparator groups, namely postmenopausal women (PMW) and age-matched men. Evaluate DA in WoCBA comparing to the aforementioned groups.Methods:Observational transversal study, using data from the portuguese registry of rheumatic diseases (Reuma.pt) from 3 portuguese centers. Adult patients (pts) with the diagnosis of RA, PsA, AS or JIA were allocated to the following groups: WoCBA (aged 18–44y), young men (YM) (18–44y), PMW (≥ 45y) and matched men (≥45y). Demographic and clinical variables are described as means or frequencies. Differences between groups regarding therapy and DA were assessed with Chi-square and ANOVA tests. Linear and logistic regression models were used to find predictors of DA and prescription patterns.Results:2133 pts were included, 69.9% female with a mean age of 55.96±15.85 y. 1437 pts were diagnosed with RA, 305 with PsA, 254 with AS and 137 with JIA. Patterns of prescription are detailed in table 1. WoCBA were less likely to be treated with glucocorticoids than PMW (OR 0.66 95%CI 0.44-0.99). WoCBA were 1.76 times more likely to be treated with MTX than YM (95%CI 1.04-2.97). Certolizumab was specially prescribed in WoCBA (OR 13.8, 95%CI 1.4-132.8). WoCBA had significantly higher DA scores than YM (DAS28 3.03±1.39 vs 2.32±1.18 and BASDAI 3.55±2.0 vs 2.43±1.66).Table 1.Prescription patternsMedications, n (%)A -WoCBA(N=256)B - Young Men(N=161)C - Post menopausal Women(N=927)D - MenN=340Chi-square testNSAIDs143 (55.9)111(68.9)472 (50.9)169 (49.7)p<0.001Glucocorticoids106 (41.4)31 (19.3)625 (67.4)154 (45.3)p<0.001csDMARDs- Methotrexate149 (58.2)60 (37.3)663 (71.5)197 (57.9)p<0.001- Leflunomide12 (4.7)4 (2.5)45 (4.9)2 (0.6)p=0.003- Sulfassalazine9 (3.5)5 (3.1)39 (4.2)9 (2.7)NS- Hydroxychloroquine36 (14.1)4 (2.5)117 (12.6)18 (5.3)p<0.001bDMARDs- Etanercept48 (18.8)29 (18.0)140 (15.1)66 (19.4)NS- Infliximab9 (3.5)11 (6.8)36 (3.9)30 (8.8)p=0.002- Adalimumab17 (6.6)15 (9.3)47 (5.1)27 (7.9)NS- Golimumab15 (5.9)18 (11.2)37 (4.0)30 (8.8)p<0.001- Certolizumab10 (3.9)0 (0)2 (0.3)2 (0.6)p<0.001- Tocilizumab12 (4.7)2 (1.2)71 (7.7)10 (2.9)p<0.001- Rituximab5 (1.9)0 (0)50 (5.4)4 (1.2)p<0.001- Abatacept0 (0)0 (0)9 (1)0 (0)NS- Secukinumab1 (0.4)4 (3.5)8 (0.9)2 (0.6)NS- Ustekinumab1 (0.4)3 (1.9)5 (0.5)0 (0)NStsDMARDs4 (1.6)1 (0.6)9 (0.9)0 (0)NSbDMARDs – biologic disease modifying antirheumatic drugs, csDMARDs – conventional synthetic disease modifying antirheumatic drugs, NSAIDs – non-steroidal anti-inflammatory drugs, tsDMARD – targeted synthetic disease modifying antirheumatic drugs, WoCBA – women of childbearing ageConclusion:Certolizumab was prescribed preferentially in WoCBA, who alsoreceived more MTX than YM. Nevertheless, DA in this group was not well controlled, which may influence future pregnancy outcomes. Ensuring tight DA control in WoCBA through proper and ideally no teratogenic medication remains an unmet clinical need.Disclosure of Interests:None declared
Collapse
|
13
|
Nunes AF, Nunes AS, Monteiro P, Martins CR, Forte H. Anisometropia in the 5th and 6th school years. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa040.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction Anisometropia is characterized by a refractive inter ocular difference greater than 1.00 dioptre (D). It is the main cause of amblyopia and loss of binocular vision. Its prevalence depends on several factors, being different values in different geographical areas of the world and in different age groups.
Objectives To estimate the frequency of anisometropia in children of the 2nd cycle of Basic Education.
Methodology A total of 519 children attending the 5th and 6th school years, from Covilhã schools, from urban and rural areas, aged between 9 and 14 years (10.8 ± 0.8 years) were enrolled in the study. The refractive error was measured with a paediatric auto refractometer (Plusoptix), without cycloplegic and in binocular conditions. Anisometropia was defined as the inter ocular difference in spherical equivalent or cylindrical, greater than 1.00 D and a separate analysis for values greater than 2.00 D.
Results The sample was symmetrically divided into genders (50.9% Male), between school grade (53% 5th year) and higher in urban areas (70.1%). The prevalence of anisometropia with cut-off points of 1.00 D and 2.00 D was 12.3% and 5.0%, respectively. There was a higher prevalence among males, in rural areas and in 6th grade. The Chi-square test (□2) shows that the difference is statistically significant only between years of schooling, with a higher prevalence in the 6th grade (p = 0.001).
Conclusion There was a slightly higher prevalence of spherical and cylindrical anisometropia (5% and 12.3%) than is reported in the literature (rates between 4.4% and 9.4%). The 6th school year presented rates significantly higher than the 5th year, which points out that anisometropia increases with age, as was also advocated by other authors. Visual screening programs in adolescence for the detection of anisometropia are fundamental, since their timely correction allows to safeguard the binocular vision.
Collapse
Affiliation(s)
- A F Nunes
- Universidade da Beira Interior
- Centro de Investigação em Ciências da Saúde (CICS)
| | - A S Nunes
- Universidade da Beira Interior
- Nucleo de Estudos em Ciências Empresariais (NECE)
| | - P Monteiro
- Universidade da Beira Interior
- Centro de Investigação em Ciências da Saúde (CICS)
| | - C R Martins
- Unidade de Saúde Pública (USP)-Agrupamento de Centros de Saúde Cova da Beira (ACeS CB)
| | - H Forte
- Unidade de Saúde Pública (USP)-Agrupamento de Centros de Saúde Cova da Beira (ACeS CB)
| |
Collapse
|
14
|
Ferreira J, Freitas F, Goncalves V, Ferreira C, Milner J, Alves P, Marinho V, Monteiro S, Baptista R, Monteiro P, Goncalves L. P6404Myocardial infarction with nonobstructive coronary arteries: does aspirin have a place in the treatment of this entity? Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Myocardial infarction with nonobstructive coronary arteries (MINOCA) is still a clinical enigma that is being increasingly recognised, as the number of coronary angiographies we perform in our centres also increase. However, the treatment for this entity is still a matter of important debate, not only due to the different causative mechanisms of this disease but also because there are no major trials regarding MINOCA treatment.
Purpose
To determine the association between acetylsalicylic acid (ASA) use after discharge and mortality after discharge in MINOCA patients admitted to a coronary care unit (CCU).
Methods
We analyzed data from 370 (11.7% of the global sample) patients admitted with MINOCA in our CCU. Patients with other final diagnoses, missing mortality data, previous acute myocardial infarction, contra-indications to aspirin and known heart failure before admission were excluded. All patients underwent transthoracic echocardiography and coronary angiography at any point during hospitalisation. After adjusting data for relevant comorbidities we then compared mortality after hospital discharge between the ASA group and the no-ASA group.
Results
Of all MINOCA patients admitted in our CCU, 84 (22.7%) were diagnosed with ST-elevation myocardial infarction (STEMI) and 286 (77.3%) with non-ST elevation myocardial infarction (NSTEMI). 296 (80%) patients received ASA after discharge. Both groups were homogeneous as we did not find any significant differences between groups regarding age (p=0.106), left ventricle ejection fraction (p=0.100), GRACE score at hospitalisation (p=0.150), Killip-Kimball class at hospitalisation (p=0.604), incidence of acute kidney injury (p=0.450), maximum c-reactive protein during stay (p=0.804) and low-density lipoprotein levels at hospitalization (p=0.055). There was also no difference in the incidence of diabetes (p=0.350), exposure to daily stress (p=0.767), active smoking (p=0.569), dyslipidemia (p=0.229), hypertension (p=0.057) and type of myocardial infarction (STEMI vs NSTEMI – p=0.215). In this MINOCA cohort (5 years follow-up) a total of 47 patients died (12.7%). ASA vs. no-ASA 1-month (3.1% vs. 0.0%, p=0.214), 6-month (4.5% vs. 1.4%, p=0.317), 1-year (5.9% vs 5.6%, p=0.900), 3-year (10.5% vs. 8.3%, p=0.668) and 5-year (13.3% vs. 12.5%, p=0.860) all-cause mortality was not significantly different. The same non-significant trend towards higher mortality with ASA was obtained when survival curves were taken into account.
Conclusions
MINOCA remains a challenging entity. In our study, the systematic use of ASA in all patients following MINOCA was not associated with better survival after long-term follow-up.
Collapse
Affiliation(s)
- J Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - F Freitas
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - V Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Alves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - V Marinho
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - R Baptista
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - L Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| |
Collapse
|
15
|
De Groot JR, De Caterina R, Kelly P, Monteiro P, Deharo JC, De Asmundis C, Lopez De Sa E, Weiss TW, Waltenberger J, Steffel J, Levy P, Bakhai A, Kirchhof P. P4756Stroke and bleeding in low, intermediate and high risk patients with atrial fibrillation treated with edoxaban: Results of the ETNA-AF Europe registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Edoxaban, a direct FXa inhibitor, has been proven non-inferior in efficacy and safer compared to warfarin in the ENGAGE AF-TIMI 48 trial. In routine care, the safety of edoxaban has not been formally established. ETNA-AF-Europe is a multinational, multi-centre, post-authorisation, observational study (NCT02944019) conducted in 825 sites in 10 European countries. Here 13,980 edoxaban-treated patients with AF were enrolled between November 2016 and February 2018, and will be followed-up for 4 years.
Methods
7,672 patients (73.4±9.26 years, 57.5% male) enrolled in the ETNA-AF Europe registry completed the one-year follow-up and were stratified into low-, intermediate- and high-risk for stroke and bleeding using the CHA2DS2-VASc and HASBLED score, respectively. We here analysed the occurrence of stroke, bleeding, intracranial haemorrhage and mortality in such categories.
Results
The mean CHA2DS2-VASc score at baseline was 3.1±1.38 and the mean HAS-BLED score was 2.5±1.1. Not surprisingly, patients at higher risk were older, had a lower body weight, more comorbidities, and a lower creatinine clearance. A higher proportion of patients at high risk received the reduced 30 mg edoxaban dose. Overall, the yearly event rates of stroke, intracranial haemorrhage, major bleeding and death were low. However, these rates increased consistently in patients with higher stroke and bleeding risks. Residual stroke risk on anticoagulation was comparable to the risk of major bleeding (Table 1).
Outcomes by stroke and bleeding risk CHA2DS2-VASc: mean 3.1±1.38 HAS-BLED: mean 2.5±1.1 All patients Low risk (0, 1 if female) Intermediate risk (1, 2 if female) High risk (≥2, 3 if female) Low risk (0, 1) Intermediate risk (2, 3) High risk (≥4) Patients, N 233 1,133 6,304 1,224 4,932 1,516 7,672 First occurrence of outcomes, n (%/year) All-cause mortality 2 (0.92%) 12 (1.11%) 242 (4.09%) 14 (1.21%) 161 (3.47%) 82 (5.78%) 257 (3.56%) Intracranial haemorrhage 0 (0.00%) 1 (0.09%) 19 (0.32%) 2 (0.17%) 10 (0.22%) 8 (0.56%) 20 (0.28%) Major bleeding 0 (0.00%) 6 (0.56%) 62 (1.05%) 2 (0.17%) 43 (0.93%) 23 (1.63%) 68 (0.95%) Stroke/SEE 0 (0.00%) 4 (0.37%) 59 (1.00%) 3 (0.26%) 41 (0.89%) 19 (1.34%) 63 (0.88%) SEE, systemic embolic event.
Conclusions
In this unselected cohort of patients with AF anticoagulated with edoxaban, high CHA2DS2-VASc and HAS-BLED scores were associated with higher risks of stroke, bleeding and death. Indirectly compared with the expected rates in non-anticoagulated patients, our data underpin the value of anticoagulants such as edoxaban in patients at high risk of stroke and bleeding.
Acknowledgement/Funding
The ETNA-AF Registry was funded by Daiichi Sankyo Europe GmbH, Munich, Germany.
Collapse
Affiliation(s)
- J R De Groot
- Academic Medical Center of Amsterdam, Cardiology, Amsterdam, Netherlands (The)
| | | | - P Kelly
- University College Dublin, Dublin, Ireland
| | - P Monteiro
- University Hospitals of Coimbra, Coimbra, Portugal
| | - J C Deharo
- Hospital La Timone of Marseille, Marseille, France
| | - C De Asmundis
- University Hospital (UZ) Brussels, Brussels, Belgium
| | | | - T W Weiss
- Karl Landsteiner Institute, Vienna, Austria
| | | | - J Steffel
- University Hospital Zurich, Zurich, Switzerland
| | - P Levy
- Université Paris-Dauphine, Paris, France
| | - A Bakhai
- Royal Free Hospital, London, United Kingdom
| | - P Kirchhof
- University of Birmingham, Birmingham, United Kingdom
| |
Collapse
|
16
|
Milner J, Monteiro S, Monteiro P, He M, Simpson C, Zaslavskiy M, Balazard F, Li L, Rousset A, Schopf S, Dellamonica D, Goncalves L. P6420Can machine learning help us improve risk stratification of diabetic patients with acute coronary syndromes? The answer will blow your mind. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.1014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Risk stratification following an acute coronary syndrome (ACS) is of utmost importance, in order to identify patients at higher risk of subsequent cardiovascular events. Diabetic patients have a significantly worse prognosis, so new risk prediction tools are important to better identify and risk stratify high risk patients within this important ACS subpopulation.
Aim
The aim of this study was to identify the best predictors of a new ACS, in a single-center database of ACS, resorting to machine learning and artificial intelligence, and to compare the Global Registry of Acute Coronary Events (GRACE) risk score's relevance for risk discrimination in a general ACS population versus a subpopulation of diabetic patients.
Methods
In a single center, 5977 patients admitted due to ACS between 2004 and 2017 and alive at discharge were studied. In the subpopulation of diabetic patients (n=3429), each covariate present in the database was analyzed separately with a Cox proportional hazard model with three terms – subpopulation belonging indicator, covariate, interaction term. The p-value of the interaction term was used to rank variables. The more significant the interaction term, the stronger the change in relationship between patients in the subpopulation and the risk of a new ACS, compared to the one in the general population.
Results
During long term follow-up, 13% of patients (n=771) experienced a second event. Kaplan-Meier curve represents how ACS free-survival depends on the GRACE risk score and group of interest. In the general population and in the subpopulation of diabetic patients, the GRACE score was used to further divide patients into 3 terciles, of which only the lower and upper tercile are shown (GRACE ≤113 and GRACE >144, respectively). The solid lines represent Kaplan-Meier curves for diabetic patients, and the dotted lines in the general population. Pink or grey colour of the curves represent the stratification level of the covariate.
Conclusions
In our model, the GRACE risk score was found to be a better discriminator of risk of futher ACS in diabetic patients than in the general ACS population. Strikingly, a higher GRACE score predicts a lower rate of readmission, probably because many patients will die in the index hospitalization or out of hospital. This finding reinforces the usefulness of the GRACE score in high risk patients and may improve risk stratisfication in diabetic post-ACS patients, making sure that they are closely followed and submitted to optimal risk factor management, in order to improve their post-ACS prognosis.
Collapse
Affiliation(s)
- J Milner
- University Hospitals of Coimbra, Cardiology Department, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology Department, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology Department, Coimbra, Portugal
| | | | | | | | | | - L Li
- AMGEN Europe, Amsterdam, Netherlands (The)
| | - A Rousset
- AMGEN Europe, Amsterdam, Netherlands (The)
| | - S Schopf
- AMGEN Europe, Amsterdam, Netherlands (The)
| | | | - L Goncalves
- University Hospitals of Coimbra, Cardiology Department, Coimbra, Portugal
| |
Collapse
|
17
|
De Caterina R, Kelly P, Monteiro P, Deharo JC, De Asmundis C, Lopez-De-Sa E, Weiss T, Waltenberger J, Steffel J, De Groot JR, Levy P, Bakhai A, Kirchhof P. P1257ETNA-AF Europe: First 1-year follow-up snapshot analysis of more than 7,500 AF patients treated with edoxaban in routine clinical practice. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Edoxaban has been approved for stroke prevention in patients with atrial fibrillation based on its comparable efficacy and superior safety compared to warfarin in the pivotal ENGAGE AF-TIMI 48 trial. ETNA-AF Europe (NCT02944019) was initiated in agreement with the EMA to evaluate benefits and risks of edoxaban treatment in unselected patients in routine clinical practice.
Methods
13,980 patients from across 825 hospital and office-based physicians from 10 European countries (Austria, Belgium, Germany, Ireland, Italy, The Netherlands, Portugal, Spain, Switzerland and United Kingdom) were enrolled, and will be followed-up for 4 years. This snapshot analysis includes baseline and first outcome data of 7,672 patients (56.3% of all enrolled patients) that have completed their first 1-year follow-up visit (mean follow-up: 343.5 days).
Results
The average age of patients was 73.4 years, the mean weight was 81.9 kg (Table 1). Frequent comorbidities include hypertension (77.2%), valvular heart disease (17.4%), congestive heart failure (5.8%) and history of myocardial infarction (4.2%). Patients receiving the 30 mg dose (22.9%) were older, had a lower creatinine clearance and had a higher risk for both stroke and bleeding as compared to those on the 60 mg dose (77.1%). Overall, the incidence of clinical events was low: all-cause mortality: 3.56%/y, major bleeding 0.95%/y, intracranial haemorrhage 0.28%/y, any stroke or systemic embolic events 0.88%/y.
Patient characteristics at Year 1 Patient characteristics All patients Edoxaban 60 mg Edoxaban 30 mg [7,672] [5,916 (77.1%)] [1,756 (22.9%)] Age [years] mean (SD) 73.4 (9.26) 71.8 (8.98) 79.1 (7.81) Body weight [kg] mean (SD) 81.9 (17.33) 84.1 (16.80) 74.3 (16.93) CrCl (CG) [mL/min] mean (SD) 75.0 (30.29) 82.5 (29.14) 51.2 (19.75) CHA2DS2-VASc mean (SD) 3.1 (1.38) 2.9 (1.34) 3.8 (1.28) HAS-BLED mean (SD) 2.5 (1.10) 2.4 (1.07) 2.9 (1.08) First occurrence of all-cause mortality (n, %/year) 257 (3.56%) 129 (2.31%) 128 (7.90%) First occurrence of intracranial haemorrhage (n, %/year) 20 (0.28%) 16 (0.29%) 4 (0.25%) First occurrence of major bleeding (n, %/year) 68 (0.95%) 49 (0.88%) 19 (1.18%) First occurrence of stroke/SEE (n, %/year) 63 (0.88%) 45 (0.81%) 18 (1.11%) CG, Cockcroft-Gault; CrCl, creatinine clearance; SD, standard deviation; SEE, systemic embolic events.
Conclusions
We found low bleeding and stroke rates in 7,672 unselected, mainly elderly AF patients treated with edoxaban in routine clinical practice. These findings were consistent across edoxaban doses and reinforce the effectiveness and safety of NOACs such as edoxaban in routine clinical care in Europe.
Acknowledgement/Funding
Daiichi Sankyo Europe GmbH, Munich, Germany
Collapse
Affiliation(s)
| | - P Kelly
- University College Dublin, HRB Stroke Clinical Trials Network Ireland, Dublin, Ireland
| | - P Monteiro
- Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | | | | | - E Lopez-De-Sa
- Hospital Universitario La Paz, IDIPAZ, Madrid, Spain
| | - T Weiss
- Karl Landsteiner Institute for Cardiometabolics and SFU, Vienna, Austria
| | | | - J Steffel
- University Hospital Zurich, Zurich, Switzerland
| | - J R De Groot
- Amsterdam University Medical Centres/University of Amsterdam, Amsterdam, Netherlands (The)
| | - P Levy
- Université Paris-Dauphine, PSL Research University, Paris, France
| | - A Bakhai
- Royal Free London NHS Foundation Trust, Chase Farm Hospital, London, United Kingdom
| | - P Kirchhof
- Institute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS Trusts, Birmingham, United Kingdom
| |
Collapse
|
18
|
Weiss T, De Caterina R, Kelly P, Monteiro P, Deharo JC, De Asmundis C, Lopez-De-Sa E, Waltenberger J, Steffel J, De Groot JR, Levy P, Bakhai A, Kirchhof P. P4766Edoxaban Treatment in routiNe clinical prActice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe): 1-year follow-up according to body mass index. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have substantially improved anticoagulation therapy for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF), and available routine care data have so far broadly confirmed the safety of different NOACs in routine practice. However, such data for edoxaban are scarce, especially in extremely low and high body weight (BW). These extreme BWs may affect the bioavailability, distribution, and half-life of NOACs and, consequently, outcomes of treatment.
Methods
We analysed outcomes in normal-weight (BMI 18.5–25) vs overweight (BMI 25–30) and obese (BMI >30) patients enrolled into the ETNA-AF-Europe observational study (NCT02944019) collecting information on patients treated with edoxaban in 825 sites in 10 European countries. This snapshot analysis set includes data of 7,672 patients (56.3% of all enrolled patients) which have completed their 1-year follow-up visit (mean follow-up: 343.5 days).
Results
Median patient age was 74 years for all patients, 76 years for patients with a BMI 18.5–25 (group 1), 75 years for patients with BMI 25–30 (group 2), and 72 for patients with a BMI >30 (group 3). CrCl was 64 mL/min for patients with a BMI 18.5–25, 68 mL/min for patients with BMI 25–30, and 72 mL/min for patients with a BMI >30. The CHA2DS2-VASc (mean 3.1±1.38) and HAS-BLED (mean 2.5±1.10) score did not differ significantly between groups. As expected, diabetes and hypertension were significantly less prevalent in leaner patients and - accordingly - inversely correlated to age.
There was no correlation between body weight and life-threatening bleeding (group 1: 0.28%; group 2: 0.40%; group 3: 0.14%). Also, stroke rates (group 1: 0.74%; group 2: 0.81%; group 3: 0.76%) did not differ between groups.
Conclusion
BMI, within the range here assessed, does not affect 1-year outcomes in European AF patients treated with edoxaban.
Acknowledgement/Funding
Daiichi Sankyo Europe GmbH, Munich, Germany
Collapse
Affiliation(s)
- T Weiss
- Karl Landsteiner Institute for Cardiometabolics, Vienna, Austria
| | | | - P Kelly
- HRB Stroke Clinical Trials Network Ireland, University College Dublin, Dublin, Ireland
| | - P Monteiro
- Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | | | | | - E Lopez-De-Sa
- Hospital Universitario La Paz, IDIPAZ, Madrid, Spain
| | | | - J Steffel
- University Hospital Zurich, Zurich, Switzerland
| | - J R De Groot
- Amsterdam University Medical Centres/University of Amsterdam, Amsterdam, Netherlands (The)
| | - P Levy
- Université Paris-Dauphine, PSL Research University, Paris, France
| | - A Bakhai
- Royal Free London NHS Foundation Trust, Chase Farm Hospital, London, United Kingdom
| | - P Kirchhof
- Institute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS Trusts, Birmingham, United Kingdom
| |
Collapse
|
19
|
Ferreira J, Monteiro S, Baptista R, Goncalves F, Monteiro P, Goncalves L. P3122Complete versus culprit-vessel only revascularization for patients with acute coronary syndromes and multivessel disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Recent randomized clinical trials have suggested that complete revascularization (CR) instead of culprit-vessel only revascularization (CVO) strategies may take a stand in the optimal management of patients admitted for acute myocardial infarction (AMI) with multivessel (MV) disease undergoing primary percutaneous coronary intervention (P-PCI). However, despite the 2017 ST-elevation acute coronary syndrome (STEMI) guidelines update with a new class of recommendation for CR, it remains controversial whether this strategy leads to better outcomes.
Purpose
To compare CR versus CV strategies during hospitalization in patients presenting with AMI with multivessel disease at P-PCI.
Methods
We analyzed data from all patients admitted with non-ST acute myocardial infarction (NSTEMI) and STEMI in a portuguese coronary care unit (CCU), between 2007 and 2016. We then evaluated potential differences of CR versus CVO with PCI during hospitalization in AMI patients with multivessel disease, defined by at least 2 different diseased main coronary vessels, saphenous vein or mammary artery conduits. We used 1:1 ratio propensity score matching to study the impact of CR on patient mortality and adjusted data for relevant risk factors at admission time.
Results
A total of 4758 patients were admitted for AMI, 2690 NSTEMI (56.5%) and 2068 STEMI (43.5%). Access to PCI records was possible in 3162 (66.5%) patients, of which 1707 (54%) underwent CR versus 1455 (46%) who underwent CVO. CVO patients were older (67.9±11.8 vs. 63.5±13.1 years, p<0.001), more diabetic (56.5% vs. 47.1%, p<0.001), hypertensive (78.4% vs. 72.2%, p<0.001), dyslipidemic (82.1% vs. 75%, p<0.001), had greater GRACE score at admission (mean score 143.4±37.2 vs. 131.2±131.2, p<0.001), had more severe coronary disease (mean number of diseased vessels – 2.56±0.6 vs. 2.18±0.4, p<0.004), reached higher Killip class (mean – 1.42±0.9 vs. 1.26±0.7, p<0.001) and had lower left ventricular ejection fraction (48.07±11.6 vs. 51.25±10.5, p<0.001). No significant differences were found in peak troponin-I release between CR and CV (44.7±69 vs. 46.9±76, respectively, p=0.468). After propensity matching, we obtained 130 CR and 133 CVO patients. In this cohort all-cause mortality was lower in CR group at 6-month (RR 0.262, CI 95% 0.071–0.962, p=0.031) and 1-year (RR 0.340, CI 95% 0.119–0.973, p=0.036) follow-up. When comparing STEMI versus NSTEMI all-cause mortality was nonsignificantly lower in CR (RR 0.394 vs. 0.226, p=0.12 vs. p=0.16).
Conclusions
In patients presenting with AMI and MV disease, CR strategy during hospitalization leads to greater 6-month and 1-year survival when compared with CVO strategy. Despite not having found significant differences when STEMI was directly compared to NSTEMI, we believe this was due to the great loss of patient numbers after propensity matching, requiring larger trials to prove the effect.
Collapse
Affiliation(s)
- J Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - R Baptista
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - F Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - L Goncalves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| |
Collapse
|
20
|
Nunes A, Fernandes D, Tuna R, Gonçalves A, Calado R, Monteiro P. Frequency of anisometropia in children in the Médio Tejo. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz034.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A Nunes
- Universidade da Beira Interior, CISC, UbiMedical, Portugal
| | - D Fernandes
- Universidade da Beira Interior, CISC, UbiMedical, Portugal
| | - R Tuna
- Universidade da Beira Interior, CISC, UbiMedical, Portugal
| | - A Gonçalves
- Unidade de Saúde Pública do Médio Tejo, Portugal
| | - R Calado
- Unidade de Saúde Pública do Médio Tejo, Portugal
| | - P Monteiro
- Universidade da Beira Interior, CISC, UbiMedical, Portugal
| |
Collapse
|
21
|
Ferreira J, Freitas F, Ferreira C, Milner J, Alves P, Marinho V, Domingues C, Santos M, Monteiro S, Monteiro P, Pego M. P1024Implantable cardioverter-defibrillator therapy in patients presenting with acute coronary syndromes - useful before 40 days? Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p1024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - F Freitas
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Alves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - V Marinho
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Domingues
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Santos
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Pego
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| |
Collapse
|
22
|
Ferreira J, Freitas F, Ferreira C, Milner J, Alves P, Marinho V, Domingues C, Santos M, Monteiro S, Monteiro P, Pego M. P1748Should we care for stress hyperglycaemia in patients admitted with acute coronary syndromes? Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - F Freitas
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Alves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - V Marinho
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Domingues
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Santos
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Pego
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| |
Collapse
|
23
|
Ferreira J, Freitas F, Ferreira C, Milner J, Alves P, Marinho V, Domingues C, Santos M, Monteiro S, Monteiro P, Pego M. 4055Should we use beta-blockers in all patients after st-segment elevation acute myocardial infarction? Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.4055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - F Freitas
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Alves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - V Marinho
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Domingues
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Santos
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Pego
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| |
Collapse
|
24
|
Ferreira J, Freitas F, Ferreira C, Milner J, Alves P, Marinho V, Domingues C, Santos M, Monteiro S, Monteiro P, Pego M. P1749Predictors of acute kidney injury in patients admitted with acute coronary syndromes in a coronary care unit. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - F Freitas
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Ferreira
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - J Milner
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Alves
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - V Marinho
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - C Domingues
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Santos
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - P Monteiro
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| | - M Pego
- University Hospitals of Coimbra, Cardiology, Coimbra, Portugal
| |
Collapse
|
25
|
Pinho J, Montezuma D, Monteiro P, Dinis-Ribeiro M, Bastos P. Endoscopic ultrasound diagnosis of Merkel cell carcinoma metastasising to pancreas. Cytopathology 2018; 29:478-481. [PMID: 29665210 DOI: 10.1111/cyt.12553] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/07/2018] [Indexed: 11/28/2022]
Affiliation(s)
- J Pinho
- Gastroenterology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal
| | - D Montezuma
- Pathology Department, Instituto Português de Oncologia do Porto, Porto, Portugal
| | - P Monteiro
- Pathology Department, Instituto Português de Oncologia do Porto, Porto, Portugal
| | - M Dinis-Ribeiro
- Gastroenterology Department, Instituto Português de Oncologia do Porto, Porto, Portugal
| | - P Bastos
- Gastroenterology Department, Instituto Português de Oncologia do Porto, Porto, Portugal
| |
Collapse
|
26
|
Pinto AE, Monteiro P, Silva G, Ayres JV, Soares J. Prognostic Biomarkers in Renal Cell Carcinoma: Relevance of DNA Ploidy in Predicting Disease-Related Survival. Int J Biol Markers 2018; 20:249-56. [PMID: 16398407 DOI: 10.1177/172460080502000408] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Objective To investigate the prognostic value of DNA ploidy, Ki-67 index and p53 expression in relation to disease-related survival in a consecutive series of patients with renal cell carcinoma (RCC). Material and methods The study group consisted of 64 RCC patients treated by radical nephrectomy. Histological type, pathological staging and nuclear anaplasia were assessed according to the WHO classification, TNM system and Fuhrman grading criteria, respectively. Ploidy was determined by DNA flow cytometry using two sampling methods (frozen vs paraffin-embedded tissue). Ki-67 and p53 were evaluated by immunohistochemistry techniques using two cutoff points (10% vs mean value) for staining interpretation. Kaplan-Meier and Cox regression analyses were used for prognostic evaluation. Results Thirty-one tumors (48.4%) showed DNA diploidy and 33 (51.6%) were DNA aneuploid. Concordance between both ploidy measurement methods was found in 85.5% of cases (p=0.0455). The mean values for Ki-67 and p53 immunostaining were 3.65% (0–23.5%) and 5.90% (0–55.9%), respectively. DNA ploidy significantly correlated with staging, tumor size (pT), nuclear grading, and Ki-67 (mean value cutoff). Ki-67 (10% cutoff) correlated with staging and pT, while p53 (mean value cutoff) was associated with Ki-67 (mean value cutoff). There were significant differences between survival curves for pathological stage, pT, nuclear grade, ploidy, Ki-67 (both cutoffs), and p53 (10% cutoff). By univariate regression analysis, stage III and stage IV, pT3, aneuploidy, high Ki-67 (both cutoffs), and p53 overexpression (10% cutoff) showed significant correlations with worse disease-related survival. In addition, DNA aneuploidy significantly correlated with poor prognosis within stages I/II (p=0.0355) and stages III/IV (p=0.0138) of the disease. Conclusion The results indicate that DNA ploidy has relevant prognostic value in RCC, adding useful information to the classic histopathological indicators of clinical outcome.
Collapse
Affiliation(s)
- A E Pinto
- Pathology Service, Instituto Português de Oncologia de Francisco Gentil, CROL, SA, Lisbon, Portugal.
| | | | | | | | | |
Collapse
|
27
|
Costa C, Feijó S, Monteiro P, Martins L, Gonçalves JR. Role of bronchoscopy in foreign body aspiration management in adults: A seven year retrospective study. Pulmonology 2018; 24:S2173-5115(17)30182-3. [PMID: 29331544 DOI: 10.1016/j.rppnen.2017.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2017] [Accepted: 12/06/2017] [Indexed: 10/18/2022] Open
Affiliation(s)
- C Costa
- Chest Department, Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.
| | - S Feijó
- Respiratory Endoscopy Unit, Chest Department, Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal; Pulmonology Department, Cento Hospitalar de Leiria, R. de Santo André, 2410-197 Leiria, Portugal
| | - P Monteiro
- Respiratory Endoscopy Unit, Chest Department, Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal
| | - L Martins
- Chest Department, Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal
| | - J Rosal Gonçalves
- Respiratory Endoscopy Unit, Chest Department, Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal
| |
Collapse
|
28
|
Alves P, Marinho V, Oliveira-Santos M, Milner J, Ferreira J, Baptista R, Monteiro S, Goncalves F, Monteiro P, Pego M. P2721Epidemiologic trends in an acute coronary unit: a 12 year report. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Clérigo V, Cardoso J, Monteiro P, Gonçalves J, Bárbara C. P173 Indications and complications of flexible bronchoscopy in very elderly patients. Chest 2017. [DOI: 10.1016/j.chest.2017.04.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
30
|
Tzoran I, Papadakis M, Brenner B, Fidalgo Á, Rivas A, Wells PS, Gavín O, Adarraga MD, Moustafa F, Monreal M, Prandoni P, Brenner B, Barba R, Di Micco P, Bertoletti L, Tzoran I, Reis A, Bosevski M, Bounameaux H, Malý R, Wells P, Papadakis M, Adarraga M, Aibar M, Alfonso M, Arcelus J, Barba R, Barrón M, Barrón-Andrés B, Bascuñana J, Blanco-Molina A, Bueso T, Cañada G, Cañas I, Chic N, del Pozo R, del Toro J, Díaz-Pedroche M, Díaz-Peromingo J, Falgá C, Fernández-Capitán C, Fidalgo M, Font C, Font L, Gallego P, García A, García M, García-Bragado F, García-Brotons P, Gavín O, Gómez C, Gómez V, González J, González-Marcano D, Grau E, Grimón A, Guijarro R, Gutiérrez J, Hernández-Comes G, Hernández-Blasco L, Hermosa-Los Arcos M, Jara-Palomares L, Jaras M, Jiménez D, Joya M, Llamas P, Lecumberri R, Lobo J, López P, López-Jiménez L, López-Reyes R, López-Sáez J, Lorente M, Lorenzo A, Maestre A, Marchena P, Martín-Martos F, Monreal M, Nieto J, Nieto S, Núñez A, Núñez M, Odriozola M, Otero R, Pedrajas J, Pérez G, Pérez-Ductor C, Peris M, Porras J, Reig O, Riera-Mestre A, Riesco D, Rivas A, Rodríguez C, Rodríguez-Dávila M, Rosa V, Ruiz-Giménez N, Sahuquillo J, Sala-Sainz M, Sampériz A, Sánchez-Martínez R, Sánchez Simón-Talero R, Sanz O, Soler S, Suriñach J, Torres M, Trujillo-Santos J, Uresandi F, Valero B, Valle R, Vela J, Vicente M, Villalobos A, Vanassche T, Verhamme P, Wells P, Hirmerova J, Malý R, Tomko T, del Pozo G, Salgado E, Sánchez G, Bertoletti L, Bura-Riviere A, Mahé I, Merah A, Moustafa F, Papadakis M, Braester A, Brenner B, Tzoran I, Antonucci G, Barillari G, Bilora F, Bortoluzzi C, Cattabiani C, Ciammaichella M, Di Biase J, Di Micco P, Duce R, Ferrazzi P, Giorgi-Pierfranceschi M, Grandone E, Imbalzano E, Lodigiani C, Maida R, Mastroiacovo D, Pace F, Pesavento R, Pinelli M, Poggio R, Prandoni P, Rota L, Tiraferri E, Tonello D, Tufano A, Visonà A, Zalunardo B, Gibietis V, Skride A, Vitola B, Monteiro P, Ribeiro J, Sousa M, Bosevski M, Zdraveska M, Bounameaux H, Calanca L, Erdmann A, Mazzolai L. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. Am J Med 2017; 130:482.e1-482.e9. [PMID: 27986523 DOI: 10.1016/j.amjmed.2016.11.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Revised: 11/03/2016] [Accepted: 11/04/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Individuals with factor V Leiden or prothrombin G20210A mutations are at a higher risk to develop venous thromboembolism. However, the influence of these polymorphisms on patient outcome during anticoagulant therapy has not been consistently explored. METHODS We used the Registro Informatizado de Enfermedad TromboEmbólica database to compare rates of venous thromboembolism recurrence and bleeding events occurring during the anticoagulation course in factor V Leiden carriers, prothrombin mutation carriers, and noncarriers. RESULTS Between March 2001 and December 2015, 10,139 patients underwent thrombophilia testing. Of these, 1384 were factor V Leiden carriers, 1115 were prothrombin mutation carriers, and 7640 were noncarriers. During the anticoagulation course, 160 patients developed recurrent deep vein thrombosis and 94 patients developed pulmonary embolism (16 died); 154 patients had major bleeding (10 died), and 291 patients had nonmajor bleeding. On multivariable analysis, factor V Leiden carriers had a similar rate of venous thromboembolism recurrence (adjusted hazard ratio [HR], 1.16; 95% confidence interval [CI], 0.82-1.64), half the rate of major bleeding (adjusted HR, 0.50; 95% CI, 0.25-0.99) and a nonsignificantly lower rate of nonmajor bleeding (adjusted HR, 0.66; 95% CI, 0.43-1.01) than noncarriers. Prothrombin mutation carriers and noncarriers had a comparable rate of venous thromboembolism recurrence (adjusted HR, 1.00; 95% CI, 0.68-1.48), major bleeding (adjusted HR, 0.75; 95% CI, 0.42-1.34), and nonmajor bleeding events (adjusted HR, 1.10; 95% CI, 0.77-1.57). CONCLUSIONS During the anticoagulation course, factor V Leiden carriers had a similar risk for venous thromboembolism recurrence and half the risk for major bleeding compared with noncarriers. This finding may contribute to decision-making regarding anticoagulation duration in selected factor V Leiden carriers with venous thromboembolism.
Collapse
Affiliation(s)
- Inna Tzoran
- Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
| | - Manolis Papadakis
- Haematology and Hemostasis Unit, Hospital Papageorgiou, Saloniki, Greece
| | - Benjamin Brenner
- Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
| | - Ángeles Fidalgo
- Department of Internal Medicine, Hospital Universitario de Salamanca, Spain
| | - Agustina Rivas
- Department of Pneumonology, Hospital Universitario Araba, Álava, Spain
| | - Philip S Wells
- Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ontario, Canada
| | - Olga Gavín
- Department of Haematology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | | | - Farès Moustafa
- Department of Emergency, Clermont-Ferrand University Hospital, France
| | - Manuel Monreal
- Department of Internal Medicine, Hospital Universitario Germans Trias i Pujol de Badalona, Universidad Católica de Murcia, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Lee FJ, Monteiro P, Baker D, Bloch M, Roth N, Finlayson R, Moore R, Hoy J, Martinez E, Carr A. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. HIV Med 2016; 17:605-14. [PMID: 26987376 DOI: 10.1111/hiv.12362] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/18/2015] [Indexed: 11/29/2022]
Abstract
OBJECTIVES The aim of the study was to compare the efficacy and safety of rosuvastatin initiation with those of switching of ritonavir-boosted protease inhibitors (PI/rs) in HIV-1-infected adults with hypercholesterolaemia and increased cardiovascular risk scores. METHODS In this open-label, multicentre study, HIV-1-infected adults on PI/r-based therapy with viral load < 50 HIV-1 RNA copies/mL, fasting total cholesterol ≥ 5.5 mmol/L (both for ≥ 6 months) and elevated cardiovascular risk (Framingham score ≥ 8% or diabetes or family history), and not on lipid-lowering therapy, were randomized to open-label rosuvastatin 10 mg/day or to PI/r switching, both with standardized diet/exercise advice. The primary endpoint was change in total cholesterol at week 12 (intention to treat). RESULTS There were 43 participants (23 on rosuvastatin). Baseline characteristics were: mean [± standard deviation (SD)] age 55 (8.5) years, 42 (98%) male, 41 (95%) white race, and mean (± SD) total cholesterol 6.2 (1.2) mmol/L. At enrolment, PI/rs were lopinavir/ritonavir (n = 22; 51%), atazanavir/ritonavir (n = 12; 28%) and darunavir/ritonavir (n = 9; 21%). The commonest PI/r substitutes were raltegravir (n = 9; 45%) and rilpivirine (n = 4; 20%). All participants were adherent through to week 12. Rosuvastatin yielded greater declines than PI/r switching in total (- 21.4% vs. - 8.7%, respectively; P = 0.003) and low-density lipoprotein (- 29.9% vs. - 1.0%, respectively; P < 0.001) cholesterol, but smaller declines in very low-density lipoprotein cholesterol and triglycerides (P < 0.01). Cholesterol lowering was greater in participants on atazanavir/ritonavir or once-daily darunavir/ritonavir (vs. lopinavir/ritonavir). More study drug-related adverse events (mostly grade 1 nausea/diarrhoea; 10 vs. one, respectively; P = 0.001) occurred with PI/r switching than with rosuvastatin. CONCLUSIONS In adults receiving a PI/r, rosuvastatin 10 mg/day for 12 weeks yielded larger decreases in total and low-density lipoprotein cholesterol than PI/r switching, and was better tolerated.
Collapse
Affiliation(s)
- F J Lee
- Clinical Research Program, Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - P Monteiro
- Infectious Diseases Unit, Hospital Cliníc, University of Barcelona, Barcelona, Spain
| | - D Baker
- East Sydney Doctors, Sydney, NSW, Australia
| | - M Bloch
- Holdsworth House Medical Practice, Sydney, NSW, Australia
| | - N Roth
- Prahran Market Clinic, Melbourne, Vic., Australia
| | - R Finlayson
- Taylor Square Private Clinic, Sydney, NSW, Australia
| | - R Moore
- Northside Clinic, Melbourne, Vic., Australia
| | - J Hoy
- Department of Infectious Diseases, The Alfred Hospital & Monash University, Melbourne, Vic., Australia
| | - E Martinez
- Infectious Diseases Unit, Hospital Cliníc, University of Barcelona, Barcelona, Spain
| | - A Carr
- Clinical Research Program, Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW, Australia
| |
Collapse
|
32
|
Wacleche V, Cleret-Buhot A, Zhang Y, Planas D, Goulet J, Monteiro P, Niessl J, Gosselin A, Tremblay C, Jenabian M, Routy J, El-Far M, Chomont N, Haddad E, Sekaly R, Ancuta P. The transcriptional program governed by RORγt favors HIV-1 replication in CCR4 + CCR6 + Th17 cells. J Virus Erad 2015. [DOI: 10.1016/s2055-6640(20)31315-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
33
|
Kaiser T, Ting JT, Monteiro P, Feng G. Transgenic labeling of parvalbumin-expressing neurons with tdTomato. Neuroscience 2015; 321:236-245. [PMID: 26318335 DOI: 10.1016/j.neuroscience.2015.08.036] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2015] [Revised: 08/08/2015] [Accepted: 08/18/2015] [Indexed: 12/22/2022]
Abstract
Parvalbumin (PVALB)-expressing fast-spiking interneurons subserve important roles in many brain regions by modulating circuit function and dysfunction of these neurons is strongly implicated in neuropsychiatric disorders including schizophrenia and autism. To facilitate the study of PVALB neuron function we need to be able to identify PVALB neurons in vivo. We have generated a bacterial artificial chromosome (BAC) transgenic mouse line expressing the red fluorophore tdTomato under the control of endogenous regulatory elements of the Pvalb gene locus (JAX # 027395). We show that the tdTomato transgene is faithfully expressed relative to endogenous PVALB expression throughout the brain. Furthermore, targeted patch clamp recordings confirm that the labeled populations in neocortex, striatum, and hippocampus are fast-spiking interneurons based on intrinsic properties. This new transgenic mouse line provides a useful tool to study PVALB neuron function in the normal brain as well as in mouse models of psychiatric disease.
Collapse
Affiliation(s)
- T Kaiser
- McGovern Institute for Brain Research at MIT, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - J T Ting
- McGovern Institute for Brain Research at MIT, Cambridge, MA 02139, USA; Human Cell Types Department, Allen Institute for Brain Science, 551 North 34th Street, Seattle, WA 98103, USA
| | - P Monteiro
- McGovern Institute for Brain Research at MIT, Cambridge, MA 02139, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; PhD Program in Experimental Biology and Biomedicine (PDBEB), Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
| | - G Feng
- McGovern Institute for Brain Research at MIT, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
| |
Collapse
|
34
|
Araújo D, Figueiredo M, Monteiro P. Endobronchial aspergilloma: An unusual presentation of pulmonary aspergillosis. Rev Port Pneumol (2006) 2015; 22:61-2. [PMID: 26299769 DOI: 10.1016/j.rppnen.2015.07.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Revised: 06/29/2015] [Accepted: 07/01/2015] [Indexed: 11/29/2022] Open
Affiliation(s)
- D Araújo
- Respiratory Department, CHAA, Guimarães, Portugal.
| | - M Figueiredo
- Respiratory Department, CHAA, Guimarães, Portugal
| | - P Monteiro
- Anatomy Department, CHAA, Guimarães, Portugal
| |
Collapse
|
35
|
Oliveira M, Machado A, Monteiro P, Cunha I, Mugeiro M. AB1070 Comparison of Ultrasound Disease Activity Score in Assessing Joint Inflammation in RA: Comparison with CDAI. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
36
|
Oliveira M, Machado A, Monteiro P, Cunha I, Mugeiro M. AB1069 Concordance Between Ultrasound and Clinical Evaluation in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Sepriano A, Araujo F, Aguiar R, Vieira R, Sousa E, Pimentel-Santos F, Sequeira G, Canhão H, Santos H, Garcia J, Pereira Silva J, Canas Silva J, Miranda L, Oliveira M, Salvador M, Bernardes M, Monteiro P, Nόvoa T, Branco J. AB0653 Retention Rate and Predictive Factors of Tnf-α Inhibitor Discontinuation in Patients with Ankylosing Spondylitis - Results from the Rheumatic Diseases Portuguese Register Reuma.Pt. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Araújo F, Sepriano A, Madureira P, Aguiar R, Bernardo A, Silva C, Sousa E, Santos F, Sequeira G, Canhão H, Santos H, Garcia J, Pereira Silva J, Canas Silva J, Oliveira M, Salvador M, Nero P, Monteiro P, Nόvoa T, Branco J. AB0660 Predictive Factors of Treatment Response to A Second Tnf-α Inhibitor in Patients with Ankylosing Spondylitis - Results from the Portuguese Register Reuma.Pt. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Curran A, Monteiro P, Domingo P, Villar J, Imaz A, Martinez E, Fernandez I, Knobel H, Podzamczer D, Iribarren JA, Penaranda M, Crespo M, Curran A, Ribera E, Navarro J, Crespo M, Monteiro P, Martinez E, Fernandez I, Domingo P, Villar J, Knobel H, Imaz A, Podzamczer D, Ibarguren M, Iribarren JA, Penaranda M, Riera M. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. J Antimicrob Chemother 2014; 69:1390-6. [DOI: 10.1093/jac/dkt517] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Leite L, Martins H, Moreira N, Mendes P, Baptista R, Goncalves F, Monteiro S, Monteiro P, Elvas L, Pego M. Acute coronary syndrome up to 35 years old: what to expect? Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p3101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Martins H, Soares FC, Moreira N, Ferreira R, Baptista R, Antonio N, Ventura M, Cristovao J, Monteiro P, Pego M. Predictors of mortality after cardiac resynchronization: a new look at the ejection fraction. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p5732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Mendes P, Mendes A, Ferreira R, Martins H, Monteiro S, Goncalves F, Belo A, Monteiro P, Mariano Pego G. Assessing renal function in acute coronary syndromes: does it really matter how we do it? Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Monteiro P, Miranda-Filho DB, Bandeira F, Lacerda HR, Chaves H, Albuquerque MFPM, Montarroyos UR, Ximenes RAA. Is arterial stiffness in HIV-infected individuals associated with HIV-related factors? Braz J Med Biol Res 2012; 45:818-26. [PMID: 22782555 PMCID: PMC3854322 DOI: 10.1590/s0100-879x2012007500116] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Accepted: 06/28/2012] [Indexed: 11/22/2022] Open
Abstract
We investigated the association between pulse wave velocity (PWV) and HIV infection, antiretroviral treatment-related characteristics, viral load, immune status, and metabolic changes in a cross-sectional study nested in a cohort of HIV/AIDS patients who have been followed for metabolic and cardiovascular changes since 2007. The study included patients recruited from the cohort (N = 261) and a comparison group (N = 82) of uninfected individuals, all enrolled from April to November 2009. Aortic stiffness was estimated using the carotid-femoral PWV (Complior-Artech, Paris, France). The groups were similar with respect to age, metabolic syndrome, diabetes mellitus, Framingham score, and use of antihypertensive and hypolipidemic medications. Hypertension was more frequent among the controls. Individuals with HIV had higher triglyceride, glucose and HDL cholesterol levels. Among individuals with HIV/AIDS, those with a nadir CD4+ T-cell count <200 cells/mm3 had a higher PWV (P = 0.01). There was no statistically significant difference when subjects were stratified by gender. Heart rate, age, male gender, and blood pressure were independently correlated with PWV. Nadir CD4+ T-cell count did not remain in the final model. There was no significance difference in PWV between HIV-infected individuals and uninfected controls. PWV was correlated with age, gender, and blood pressure across the entire population and among those infected with HIV. We recommend cohort studies to further explore the association between inflammation related to HIV infection and/or immune reconstitution and antiretroviral use and PWV.
Collapse
Affiliation(s)
- P Monteiro
- Serviço de Doenças Infecciosas, Universidade de Pernambuco, Recife, PE, Brasil.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Amorim M, Moreira A, Condeco J, Monteiro P, Marques A, Summavielle T. P-1201 - Antipsychotic therapy and biochemical laboratory profile characterization of a sample of patients diagnosed with schizophrenia. Eur Psychiatry 2012. [DOI: 10.1016/s0924-9338(12)75368-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
45
|
Serra S, Monteiro P, Vaz A, Pires E, Monteiro R, Inês L, Salvador MJ, Bernardo J, Malcata A. [Septic arthritis and gout--a case report]. Acta Reumatol Port 2012; 37:70-74. [PMID: 22781515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The authors describe a 54 year-old male patient, admitted after presenting in the emergency room with acute oligoarthritis affecting the shoulders and right tibiotarsal and sternoclavicular joints, with a week's duration. He was non-febrile and related a purulent discharge from the stump of a traumatic amputation of the left thumb, starting a few days prior to the presenting complaints. There was a previous history of gouty arthritis and moderate alcoholism. Lab work revealed an elevation of the acute phase markers, with marked neutrophilia. Upon admittance, the patient underwent arthrocentesis, revealing a purulent discharge with sodium monourate crystals, which cultured positively for meticillin-sensitive Staphylococcus aureus. Besides antibiotherapy, on Day 5 the patient presented with a cervical abscess with extension to mediastinum; the abscess was drained by a cardiothoracic surgeon, and the right sternoclavicular and first costochondral articulations were found to be destroyed. The authors note that, although it is a rare occurrence septic arthritis can coexist with gout, while discussing the possible mecanisms of this association, as well as particular details of the clinical case presented.
Collapse
Affiliation(s)
- S Serra
- Serviço de Reumatologia, Hospitais da Universidade de Coimbra, Portugal.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Wang M, Yan G, Yue W, Siu C, Tse H, Perperidis A, Cusack D, White A, Macgillivray T, Mcdicken W, Anderson T, Ryabov V, Shurupov V, Suslova T, Markov V, Elmstedt N, Ferm Widlund K, Lind B, Brodin LA, Westgren M, Mantovani F, Barbieri A, Bursi F, Valenti C, Quaglia M, Modena M, Peluso D, Muraru D, Dal Bianco L, Beraldo M, Solda' E, Tuveri M, Cucchini U, Al Mamary A, Badano L, Iliceto S, Goncalves A, Almeria C, Marcos-Alberca P, Feltes G, Hernandez-Antolin R, Rodriguez H, Maroto L, Silva Cardoso J, Macaya C, Zamorano J, Squarciotta S, Innocenti F, Guzzo A, Bianchi S, Lazzeretti D, De Villa E, Vicidomini S, Del Taglia B, Donnini C, Pini R, Mennie C, Salmasi AM, Kutyifa V, Nagy V, Edes E, Apor A, Merkely B, Nyrnes S, Lovstakken L, Torp H, Haugen B, Said K, Shehata A, Ashour Z, El-Tobgy S, Cameli M, Bigio E, Lisi M, Righini F, Franchi F, Scolletta S, Mondillo S, Gayat E, Weinert L, Yodwut C, Mor-Avi V, Lang R, Hrynchyshyn N, Kachenoura N, Diebold B, Khedim R, Senesi M, Redheuil A, Mousseaux E, Perdrix L, Yurdakul S, Erdemir V, Tayyareci Y, Memic K, Yildirimturk O, Aytekin V, Gurel M, Aytekin S, Gargani L, Fernandez Cimadevilla C, La Falce S, Landi P, Picano E, Sicari R, Smedsrud MK, Gravning J, Eek C, Morkrid L, Skulstad H, Aaberge L, Bendz B, Kjekshus J, Edvardsen T, Bajraktari G, Hyseni V, Morina B, Batalli A, Tafarshiku R, Olloni R, Henein M, Mjolstad O, Snare S, Folkvord L, Helland F, Torp H, Haraldseth O, Grimsmo A, Haugen B, Berry M, Zaghden O, Nahum J, Macron L, Lairez O, Damy T, Bensaid A, Dubois Rande J, Gueret P, Lim P, Nciri N, Issaoui Z, Tlili C, Wanes I, Foudhil H, Dachraoui F, Grapsa J, Dawson D, Nihoyannopoulos P, Gianturco L, Turiel M, Atzeni F, Sarzi-Puttini P, Stella D, Donato L, Tomasoni L, Jung P, Mueller M, Huber T, Sevilmis G, Kroetz F, Sohn H, Panoulas V, Bratsas A, Dawson D, Nihoyannopoulos P, Raso R, Tartarisco G, Gargani L, La Falce S, Pioggia G, Picano E, Gargiulo P, Petretta M, Cuocolo A, Prastaro M, D'amore C, Vassallo E, Savarese G, Marciano C, Paolillo S, Perrone Filardi P, Aggeli C, Felekos I, Roussakis G, Poulidakis E, Pietri P, Toutouzas K, Stefanadis C, Kaladaridis A, Skaltsiotis I, Kottis G, Bramos D, Takos D, Matthaios I, Agrios I, Papadopoulou E, Moulopoulos S, Toumanidis S, Carrilho-Ferreira P, Cortez-Dias N, Jorge C, Silva D, Silva Marques J, Placido R, Santos L, Ribeiro S, Fiuza M, Pinto F, Stoickov V, Ilic S, Deljanin Ilic M, Kim W, Woo J, Bae J, Kim K, Descalzo M, Rodriguez J, Moral S, Otaegui I, Mahia P, Garcia Del Blanco L, Gonzalez Alujas T, Figueras J, Evangelista A, Garcia-Dorado D, Takeuchi M, Kaku K, Otani K, Iwataki M, Kuwaki H, Haruki N, Yoshitani H, Otsuji Y, Kukucka M, Pasic M, Unbehaun A, Dreysse S, Mladenow A, Kuppe H, Hetzer R, Rajamannan N, Yurdakul S, Tayyareci Y, Tanrikulu A, Yildirimturk O, Aytekin V, Aytekin S, Kristiansson L, Gustafsson S, Lindmark K, Henein MY, Evdoridis C, Stougiannos P, Thomopoulos M, Fosteris M, Spanos P, Sionis G, Giatsios D, Paschalis A, Sakellaris C, Trikas A, Yong ZY, Boerlage-Van Dijk K, Koch K, Vis M, Bouma B, Piek J, Baan J, Abid L, Frikha Z, Makni K, Maazoun N, Abid D, Hentati M, Kammoun S, Barbier P, Staron A, Cefalu' C, Berna G, Gripari P, Andreini D, Pontone G, Pepi M, Ring L, Rana B, Ho S, Wells F, Yurdakul S, Tayyareci Y, Yildirimturk O, Dogan A, Aytekin V, Aytekin S, Karaca O, Guler G, Guler E, Gunes H, Alizade E, Agus H, Gol G, Esen O, Esen A, Turkmen M, Agricola E, Ingallina G, Ancona M, Maggio S, Slavich M, Tufaro V, Oppizzi M, Margonato A, Orsborne C, Irwin B, Pearce K, Ray S, Garcia Alonso C, Vallejo N, Labata C, Lopez Ayerbe J, Teis A, Ferrer E, Nunez Aragon R, Gual F, Pedro Botet M, Bayes Genis A, Santos CM, Carvalho M, Andrade M, Dores H, Madeira S, Cardoso G, Ventosa A, Aguiar C, Ribeiras R, Mendes M, Petrovic M, Petrovic M, Milasinovic G, Vujisic-Tesic B, Nedeljkovic I, Zamaklar-Trifunovic D, Petrovic I, Draganic G, Banovic M, Boricic M, Villarraga H, Molini-Griggs Bs C, Silen-Rivera Bs P, Payne Mph Ms B, Koshino Md Phd Y, Hsiao Md J, Monivas Palomero V, Mingo Santos S, Mitroi C, Garcia Lunar I, Garcia Pavia P, Castro Urda V, Toquero J, Gonzalez Mirelis J, Cavero Gibanel M, Fernandez Lozano I, Oko-Sarnowska Z, Wachowiak-Baszynska H, Katarzynska-Szymanska A, Trojnarska O, Grajek S, Bellavia D, Pellikka P, Dispenzieri A, Oh JK, Polizzi V, Pitrolo F, Musumeci F, Miller F, Ancona R, Comenale Pinto S, Caso P, Severino S, Cavallaro C, Vecchione F, D'onofrio A, Calabro' R, Maceira Gonzalez AM, Ripoll C, Cosin-Sales J, Igual B, Salazar J, Belloch V, Cosin-Aguilar J, Pinamonti B, Iorio A, Bobbo M, Merlo M, Barbati G, Massa L, Faganello G, Di Lenarda A, Sinagra GF, Ishizu T, Seo Y, Enomoto M, Kameda Y, Ishibashi N, Inoue M, Aonuma K, Saleh A, Matsumori A, Negm H, Fouad H, Onsy A, Hamodraka E, Paraskevaidis I, Kallistratos M, Lezos V, Zamfir T, Manetos C, Mavropoulos D, Poulimenos L, Kremastinos D, Manolis A, Citro R, Rigo F, Ciampi Q, Patella M, Provenza G, Zito C, Tagliamonte E, Rotondi F, Silvestri F, Bossone E, Monivas Palomero V, Mingo Santos S, Beltran Correas P, Gutierrez Landaluce C, Mitroi C, Garcia Lunar I, Gonzalez Mirelis J, Cavero Gibanel M, Gomez Bueno M, Segovia Cubero J, Beladan C, Matei F, Popescu B, Calin A, Rosca M, Boanta A, Enache R, Savu O, Usurelu C, Ginghina C, Ciobanu AO, Dulgheru R, Magda S, Dragoi R, Florescu M, Vinereanu D, Silva Marques J, Robalo Martins S, Jorge C, Calisto C, Goncalves S, Ribeiro S, Barrigoto I, Carvalho De Sousa J, Almeida A, Nunes Diogo A, Sargento L, Satendra M, Sousa C, Lousada N, Palma Reis R, Schiano Lomoriello V, Esposito R, Santoro A, Raia R, Schiattarella P, Dores E, Galderisi M, Mansencal N, Caille V, Dupland A, Perrot S, Bouferrache K, Vieillard-Baron A, Jouffroy R, Moceri P, Liodakis E, Gatzoulis M, Li W, Dimopoulos K, Sadron M, Seguela PE, Arnaudis B, Dulac Y, Cognet T, Acar P, Shiina Y, Gatzoulis M, Uemura H, Li W, Kupczynska K, Kasprzak J, Michalski B, Lipiec P, Carvalho V, Almeida AMG, David C, Marques J, Silva D, Cortez-Dias N, Ferreira P, Amaro M, Costa P, Diogo A, Tritakis V, Ikonomidis I, Paraskevaidis I, Lekakis J, Tzortzis S, Kadoglou N, Papadakis I, Trivilou P, Koukoulis C, Anastasiou-Nana M, Bombardini T, Picano E, Gherardi S, Arpesella G, Maccherini M, Serra W, Magnani G, Del Bene R, Pasanisi E, Sicari R, Startari U, Panchetti L, Rossi A, Piacenti M, Morales M, Mansencal N, El Hajjaji I, El Mahmoud R, Digne F, Dubourg O, Gargani L, Agoston G, Moreo A, Pratali L, Moggi Pignone A, Pavellini A, Doveri M, Musca F, Varga A, Picano E, Pratali L, Faita F, Rimoldi S, Sartori C, Alleman Y, Salinas Salmon C, Villena M, Scherrer U, Picano E, Sicari R, Baptista R, Serra S, Castro G, Martins R, Salvador M, Monteiro P, Silva J, Szudi L, Temesvary A, Fekete B, Kassai I, Szekely L, Abdel Moneim SS, Martinez M, Mankad S, Bernier M, Dhoble A, Pellikka P, Chandrasekaran K, Oh J, Mulvagh S, Hong GR, Kim JY, Lee SC, Choi SH, Sohn IS, Seo HS, Choi JH, Cho KI, Yoon SJ, Lim SJ, Lipiec P, Wejner-Mik P, Kusmierek J, Plachcinska A, Szuminski R, Kasprzak J, Stoebe S, Tarr A, Trache T, Hagendorff A, Mor-Avi V, Yodwut C, Jenkins C, Kuhl H, Nesser H, Marwick T, Franke A, Niel J, Sugeng L, Lang R, Gustafsson S, Henein M, Soderberg S, Lindmark K, Lindqvist P, Necas J, Kovalova S, Saha SK, Kiotsekoglou A, Toole R, Govind S, Gopal A, Amzulescu MS, Florian A, Bogaert J, Janssens S, Voigt J, Parisi V, Losi M, Parrella L, Contaldi C, Chiacchio E, Caputi A, Scatteia A, Buonauro A, Betocchi S, Rimbas R, Dulgheru R, Mihaila S, Vinereanu D, Caputo M, Navarri R, Innelli P, Urselli R, Capati E, Ballo P, Furiozzi F, Favilli R, Mondillo S, Lindquist R, Miller A, Reece C, O'leary P, Cetta F, Eidem BW, Cikes M, Gasparovic H, Bijnens B, Velagic V, Kopjar T, Biocina B, Milicic D, Ta-Shma A, Nir A, Perles Z, Gavri S, Golender J, Rein A, Pinnacchio G, Barone L, Battipaglia I, Cosenza A, Marinaccio L, Coviello I, Scalone G, Sestito A, Lanza G, Crea F, Cakal S, Eroglu E, Ozkan B, Kulahcioglu S, Bulut M, Koyuncu A, Acar G, Alici G, Dundar C, Esen A, Labombarda F, Zangl E, Pellissier A, Bougle D, Maragnes P, Milliez P, Saloux E, Aggeli C, Lagoudakou S, Felekos I, Gialafos E, Poulidakis E, Tsokanis A, Roussakis G, Stefanadis C, Nagy A, Kovats T, Apor A, Vago H, Toth A, Sax B, Kovacs A, Merkely B, Elnoamany MF, Badran H, Abdelfattah I, Khalil T, Salama M, Butz T, Taubenberger C, Thangarajah F, Meissner A, Van Bracht M, Prull M, Yeni H, Plehn G, Trappe H, Rydman R, Bone D, Alam M, Caidahl K, Larsen F, Staron A, Gasior Z, Tabor Z, Sengupta P, Liu D, Niemann M, Hu K, Herrmann S, Stoerk S, Morbach C, Knop S, Voelker W, Ertl G, Weidemann F, Cawley P, Hamilton-Craig C, Mitsumori L, Maki J, Otto C, Astrom Aneq M, Nylander E, Ebbers T, Engvall J, Arvanitis P, Flachskampf F, Duvernoy O, De Torres Alba F, Valbuena Lopez S, Guzman Martinez G, Gomez De Diego J, Rey Blas J, Armada Romero E, Lopez De Sa E, Moreno Yanguela M, Lopez Sendon J, Aggeli C, Felekos I, Poulidakis E, Trikalinos N, Siasos G, Aggeli A, Roussakis G, Stefanadis C, Tomaszewski A, Kutarski A, Tomaszewski M, Ikonomidis I, Lekakis J, Tritakis V, Tzortzis S, Kadoglou N, Papadakis I, Trivilou P, Anastasiou-Nana M, Koukoulis C, Paraskevaidis I, Vriz O, Driussi C, Bettio M, Pavan D, Bossone E, Antonini Canterin F, Doltra Magarolas A, Fernandez-Armenta J, Silva E, Solanes N, Rigol M, Barcelo A, Mont L, Berruezo A, Brugada J, Sitges M, Ciciarello FL, Mandolesi S, Fedele F, Agati L, Marceca A, Rhee S, Shin S, Kim S, Yun K, Yoo N, Kim N, Oh S, Jeong J, Alabdulkarim N. Poster Session 4: Friday 9 December 2011, 14:00-18:00 * Location: Poster Area. European Journal of Echocardiography 2011. [DOI: 10.1093/ejechocard/jer216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
47
|
Neves TR, Covita A, Soares M, Monteiro P, Nogueira R, Lima MS, Monteiro H. Bladder metastasis of gastric adenocarcinoma. Report of 2 cases and bibliographic review. ARCH ESP UROL 2011; 64:544-550. [PMID: 21791721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
OBJECTIVE Metastases to the urinary bladder are rare, representing less than 2% of bladder tumors. We report two cases of bladder involvement by primary gastric adenocarcinoma and perform a bibliographic review of the literature on this subject. METHODS A search for published data was performed in the PubMed database using the key words "bladder", "secondary malignant tumors" and "metastatic gastric carcinoma". We reviewed the two cases of secondary bladder involvement by primary gastric adenocarcinoma managed at our institution. RESULTS Case 1: 62 year old female presenting with irritative LUTS, hypogastric pain and constitutional symptoms, with bilateral hydronephrosis. After bilateral nephrostomy, bladder wall biopsies revealed poorly differentiated metastatic gastric carcinoma. Case 2: 41 year old male with gastric adenocarcinoma diagnosed by endoscopic biopsy with pancreatic involvement, under neoadjuvant chemotherapy regimen, with sporadic macroscopic hematuria. Cistoscopy revealed a protuberant bladder mass with biopsies conclusive for secondary bladder involvement by gastric carcinoma. CONCLUSION Bladder metastasis from primary gastric adenocarcinoma usually means advanced disease with multiple metastatic involvement and peritoneal dissemination. The overall prognosis is very poor.
Collapse
Affiliation(s)
- Tiago Rafael Neves
- Urology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, Lisbon, Portugal.
| | | | | | | | | | | | | |
Collapse
|
48
|
Serra S, Monteiro P, Pires E, Vieira R, Telechea O, Inês L, Salvador MJ, Malcata A. [Relapsing polychondritis, interstitial granulomatous dermatitis and antiphospholipid syndrome: an unusual clinical association]. Acta Reumatol Port 2011; 36:292-297. [PMID: 22113604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The authors describe the case of a 49 year-old male patient with a 3-year history of antiphospholipid syndrome, admitted after presenting in the emergency room with erythematous nodular skin lesions, affecting the face and neck, with a week's duration. Local biopsies were suggestive of interstitial granulomatous dermatitis. The patient described lesions compatible with bilateral auricular chondritis, two weeks prior to the appearance of the nodules, which resolved spontaneously after 3 days. There was a previous episode of nasal chondritis, two years previously, and another episode starting at the 7th day of hospitalization. These findings, taken together with a diagnosis of seronegative polyarthritis established 5 years before the current events, lead to a diagnosis of relapsing polychondritis.
Collapse
Affiliation(s)
- S Serra
- Serviço de Reumatologia, Hospitais da Universidade de Coimbra, Portugal.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Matafome P, Louro T, Rodrigues L, Crisóstomo J, Nunes E, Amaral C, Monteiro P, Cipriano A, Seiça R. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011; 27:54-62. [PMID: 21218508 DOI: 10.1002/dmrr.1157] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress. However, the pathophysiology of NAFLD in type 2 diabetes with hyperlipidaemia is not fully known, as well as the utility of the commonly prescribed anti-diabetic and lipid-lowering drugs in ameliorating liver injury markers. METHODS hepatic complications of type 2 diabetes with hyperlipidaemia and the effects of atorvastatin and metformin, isolated and in association, in systemic and hepatic inflammatory and oxidative stress markers were tested using genetic type 2 diabetic Goto-Kakizaki rats fed with a high-fat diet. RESULTS the high-fat diet aggravated the overall metabolic state and the hepatic markers of injury. All treatments decreased fasting glycaemia, insulin resistance and free fatty acid levels. Combined treatment further decreased C-reactive protein (CRP), adiponectin, liver tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), systemic and hepatic oxidative stress and portal inflammation. CONCLUSIONS our data provides evidence of a greater benefit with a combination of atorvastatin and metformin in improving liver injury in type 2 diabetes with hyperlipidaemia.
Collapse
Affiliation(s)
- P Matafome
- Laboratory of Physiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; Center of Ophthalmology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Barthelemy O, Silvain J, Brieger D, Bellemain-Appaix A, Cayla G, Beygui F, Lancar R, Collet JP, Mercadier A, Montalescot G, Cha KS, Nam YH, Kim JH, Park SY, Park TH, Kim MH, Kim YD, Lee HC, Ahn MS, Hong TJ, Blanco R, Blanco F, Szarfer J, Garcia Escudero A, Gigena G, Gagliardi J, Rodriguez A, Sarmiento R, Affatatto S, Riccitelli M, Petris A, Datcu MD, Pop C, Radoi M, Arsenescu-Georgescu C, Petrescu I, Petrescu L, Serban L, Nechita E, Tatu-Chitoiu G, Tatu-Chitoiu G, Dorobantu M, Benedek I, Craiu E, Sinescu C, Ionescu DD, Radoi M, Pop C, Ginghina C, Minescu B, Izzo A, Mantovani P, Tomasi L, Dall'oglio L, Bonatti S, Rosiello R, Romano M, Agostini F, Zanini R, Zhao ZY, Wu YJ, Li JJ, Yany YJ, Qian HY, Tang YD, Timoteo AT, Toste A, Lousinha A, Ramos R, Oliveira JA, Ferreira ML, Ferreira RC, Cabades C, Diez Gil JL, Aguar P, Sanmiguel D, Lopez-March A, Marmol R, Guerra L, Girbes V, Ferrando J, Rincon De Arellano A, Timoteo AT, Ramos R, Toste A, Oliveira JA, Patricio L, Ferreira ML, Ferreira RC, Blondal M, Ainla T, Marandi T, Eha J, Timoteo AT, Oliveira MM, Silva MN, Cunha PS, Feliciano J, Silva S, Ferreira RC, Silva B, Oliveira R, Caires G, Drumond A, Araujo J, Suarez-Barrientos A, Vivas D, Castro-Ferreira F, Nunez-Gil I, Franco E, Kanovsky J, Garcia-Rubira JC, Fernandez-Ortiz A, Fuster V, Macaya C, Ibanez Cabeza B, Salinger S, Perisic Z, Milic D, Stanojlovic T, Apostolovic S, Kala P, Obradovic S, Djordjevic-Radojkovic D, Damjanovic M, Koracevic G, Kostic T, Khan MA, Vrapi F, Naeem K, Davar J, Hristova K, Parenica J, Hristova K, Pencheva G, Radeva R, Milanov S, Trambaiolo P, Poli M, De Luca M, Lukic V, Mustilli M, Corsi F, Poloczek M, Simonetti M, Ferraiuolo G, Fareed A, Oraby M, Nasr GM, Maklady F, Dupouy P, Sorensen JT, Terkelsen CJ, Lassen JF, Prymusova K, Trautner S, Christensen EF, Nielsen TT, Botker HE, Andersen HR, Thygesen KA, Checco L, Usmiani T, Sbarra PL, Boffini M, Kubkova L, Saviolo R, Grasso C, Conrotto F, Marchetti M, Rinaldi M, Marra S, Moscoso Costa F, Ferreira J, Raposo L, Aguiar C, Spinar J, Trabulo M, Silva JA, Faria R, Mimoso J, Marques N, Trigo J, Marques V, Gomes V, Swiatkowski A, Kowalczyk J, Olinic D, Lenarczyk R, Chodor P, Honisz G, Was T, Swierad M, Sredniawa B, Polonski L, Kalarus Z, Postadzhiyan AS, Velinov H, Homorodean C, Velchev V, Hazarbasanov D, Apostolova M, Finkov B, Petrovic M, Panic G, Jovelic A, Canji T, Srdanovic I, Popov T, Ober M, Golubovic M, Pavlovic K, Cemerlic-Adjic N, Bro-Jeppesen J, Kjaergaard J, Wanscher MC, Nielsen SL, Rasmussen LS, Hassager C, Bro-Jeppesen J, Olinic M, Kjaergaard J, Wanscher MC, Rasmussen LS, Hassager C, Khan M, Crolla E, Morley H, Akeroyd L, Beaini Y, Morley C, Andrioaia C, Dores H, Leal S, Rosario I, Abecasis J, Monge J, Correia MJ, Arroja I, Fonseca C, Aleixo A, Silva A, Condac A, Bekeredjian RH, Krumsdorf U, Rottbauer W, Katus HA, Pleger S, Providencia RA, Silva J, Barra S, Gomes PL, Seca L, Masmoudi M, Botelho A, Quintal N, Mota P, Leitao-Marques AM, Silva B, Santos N, Cafe H, Faria P, Serrao M, Gomes S, Berdaoui B, Oliveira R, Caires G, Drumond A, Araujo J, Roussel JC, Senage T, Perigaud C, Habash O, Michel M, Treilhaud M, Labidi S, Despins P, Trochu JN, Baron O, Duveau D, Kitsiou AN, Giannakopoulos K, Papadimitriou G, Karas S, Babic Z, Nikolic Heitzler V, Tapia Ballesteros C, Milicic D, Bergovec M, Raguz M, Mirat J, Strozzi M, Plazonic Z, Giunio L, Steiner R, Freynhofer M, Brozovic I, Hernandez Luis C, Bruno V, Leherbauer L, Djurkovic M, Jarai R, Willheim M, Huebl W, Wojta J, Huber K, Vogel B, Hahne S, Sandin MG, Kozanli I, Kalla K, Jarai R, Freynhofer M, Smetana P, Geppert A, Unger G, Huber K, Simoes Marques Assuncao Caetano AF, Barra S, Vegas JM, Silva J, Providencia R, Faustino C, Botelho A, Mota P, Leitao Marques A, Ariza Sole A, Sanchez Salado JC, Lorente Tordera V, Martinez Garcia V, Andion R, Salazar Mendiguchia Y Garcia J, Gomez Hospital JA, Maristany Daunert J, Berdejo Gago FJ, Esplugas Oliveras E, Brzozowska-Czarnek A, Urbanik A, Kakouros N, Kakouros S, Lekakis J, Martinez N, Rizos J, Kokkinos D, Venevtseva J, Melnikov A, Valiahmetov M, Gomova T, Perelomova I, Ferrer Hita JJ, Bosa-Ojeda F, Sanchez-Grande-Flecha A, Gonzalez IA, Yanes-Bowden G, Vargas-Torres MJ, Rodriguez-Gonzalez A, Rubio-Iglesias-Garcia C, Dominguez-Rodriguez A, Enjuanes-Grau C, Marrero-Rodriguez F, Parepa I, Suceveanu AI, Suceveanu A, Alvarado M, Mazilu L, Alexandrescu L, Dumitru E, Miu V, Jitari V, Craiu E, Voinea FL, Balachandran KP, Schofield R, Sankaranarayanan R, Amat IJ, Helm K, Crowe C, Singh R, Mcdonald J, Chuen MJ, Kobusiak-Prokopowicz M, Preglowska M, Mysiak A, Doi T, Sakoda T, San Roman JA, Akagami T, Naka T, Tsujino T, Masuyama T, Ohyanagi M, Kume N, Mitsuoka H, Hayashida K, Tanaka M, Biasucci LM, Garcia Gonzalez MJ, Della Bona R, Biasillo G, Leo M, Zaninotto M, Plebani M, Crea F, Biasucci LM, Dellabona R, Leo M, Biasillo G, Arroyo Ucar E, Zaninotto M, Plebani M, Crea F, Cavusoglu Y, Gok B, Birdane A, Demirustu C, Gorenek B, Unalir A, Ata N, Hernandez Garcia C, Timuralp B, Nikulina N, Yakushin SS, Nikulina N, Yakushin SS, Furmenko GI, Akinina SA, Dores H, Ingrid R, Leal S, Dorta Martin M, Correia MJ, Bronze L, Monge J, Arroja I, Fonseca C, Aleixo A, Silva A, Djambazov S, Zhivkov A, Maznev I, Marrero Rodriguez F, Ingeliev M, Slavov R, Cvetkova N, Patarinski V, Groch L, Horak J, Dimitrov N, Hayrapetyan HG, Raposeiras Roubin S, Abu-Assi E, Dragu R, Cabanas-Grandio P, Agra-Bermejo R, Garcia-Acuna JM, Pena-Gil C, Gonzalez-Juanatey JR, Barra SNC, Silva J, Providencia R, Seca L, Gomes P, Kapeliovich M, Leitao Marques A, Daly MJ, Mc Keag NA, Mc Cann CJ, Cardwell C, Young IS, Adgey AAJ, Mikhalchikova N, Burova N, Zaccaria M, Hammerman H, Palmisano P, Palumbo V, Ciccone MM, Favale S, Chen KC, Yin WH, Liu JH, Goncalves S, Santos JF, Amador P, Silva D, Soares LN, Zahidova K, Guliyev F, Zahidov N, Carrilho-Ferreira P, Cortez-Dias N, Marques JS, Silva D, Jorge C, Robalo Martins S, Cortez-Dias N, Almeida Ribeiro M, Calisto C, Carvalho De Sousa J, Lopes MG, Cortez-Dias N, Calisto C, Silva D, Jorge C, Carrilho-Ferreira P, Silva Marques J, Jorge C, Robalo Martins S, Correia MJ, Carvalho De Sousa J, Lopes MG, Uthoff H, Thalhammer C, Potocki M, Reichlin T, Noveanu M, Aschwanden M, Silva Marques J, Staub D, Arenja N, Socrates T, Mueller C, Zhao Y, Wu X, Xue Q, Gao L, Lin H, Wang S, Carilho Ferreira P, Watanabe K, Kawamura A, Seko T, Omura A, Sakabe S, Kasai A, Starodubova AV, Storozhakov G, Kisliak O, Hautieva F, Robalo Martins S, Tursheva M, Fedotova N, Di Maio RC, Mclaughlin J, Allen JD, Anderson JMC, Adgey AAJ, Khaled Nagi H, Abed N, Tayeh O, Almeida Ribeiro M, Farok W, Mousa A, Neuzil P, Skoda J, Petru J, Sediva L, Kralovec S, Holy F, Holdova K, Jehlicka P, Calisto C, Plasil P, Reddy VY, Alabakovska S, Labudovic D, Jovanova S, Tosheska K, Alabakovski M, Jeevaratnam K, Tee SP, Zhang Y, Fiuza M, Guzadhur L, Gurung IS, Duehmke R, Grace AA, Lei M, Huang CL, Ishibashi Y, Yamauchi M, Akashi Y, Musha H, Lopes MG, Miyake F, Hnatek T, Kamenik L, Sedlon P, Luxova J, Steuerova B, Skvaril J, Cernohous M, Zavoral M, Ratkovic N, Milicevic P, Nemanja Djenic NR, Aleksandra Jovelic AJ, Slobodan Obradovic SO, Branko Gligic BG, Kletsiou E, Giannakopoulou M, Bozas E, Iliodromitis EK, Anastasiou-Nana M, Papathanassoglou EDE, Panic M, Anton M, Anton G, Muraru M, Stanojlovic T, Salinger Martinovic S, Radosavljevic M, Glasnovic J, Stanojevic D, Zivkovic M, Cortez-Dias N, Stankovic I, Jorge C, Calisto C, Silva D, Carrilho-Ferreira P, Silva Marques J, Robalo Martins S, Pessoa T, Fiuza M, Lopes MG, Aspromonte N, Milicevic D, Ronco C, Tubaro M, Santini M, Colivicchi F, Aiello A, Cruz D, Anzoletti Boscolo A, Vianello G, Valle R, Cavusoglu Y, Kalezic T, Parspour A, Birdane A, Tek M, Gorenek B, Unalir A, Ata N, Lee WP, Ong BB, Watkins S, Datta D, Kafedzic S, Halcox JPJ, Providencia RA, Barra S, Gomes PL, Seca L, Silva J, Botelho A, Quintal N, Pais JR, Mota P, Ilic I, Leitao-Marques AM, Nikishin AG, Pirnazarov MM, Nurbaev TA, Motovska Z, Fischerova M, Osmancik P, Maly M, Widimsky P, Pavli E, Cerovic M, Dibra A, Mehilli J, Dibra L, Schoemig A, Kastrati A, Carmo P, Ferreira J, Aguiar C, Almeida M, Raposo L, Putnikovic B, Teles R, Goncalves P, Brito J, Silva A, D'ascenzo F, Gonella A, Longo G, Pullara A, Moretti C, Sciuto F, Neskovic A, Omede' P, Biondi Zoccai G, Trevi GP, Sheiban I, Santos N, Serrao M, Cafe H, Silva B, Oliveira R, Caires G, Rott D, Drumond A, Araujo J, Cafe HM, Silva B, Santos N, Faria P, Oliveira R, Pereira A, Caires G, Pereira D, Leibowitz D, Freitas D, Araujo J, Pittl U, Schratter A, Klemm T, Lehmann D, Demmin K, Mende M, Schuler G, Thiele H, Monhart Z, Salazar Mendiguchia Y Garcia J, Ariza Sole A, Martinez Garcia V, Sanchez Salado JC, Lorente Tordera V, Ortiz Berbel D, Rabasa Baraibar JM, Esplugas Oliveras E, Monge J, Leal S, Reissigova J, Dores H, Bronze Carvalho L, Rosario I, Abecasis J, Correia MJ, Leitao A, Aleixo A, Silva A, Leone AM, De Caterina A, Grunfeldova H, Aurelio A, Sciahbasi A, Lioy E, Trani C, Burzotta F, Porto I, Rebuzzi AG, Crea F, Trusinskis K, Juhnevica D, Jansky P, Strenge K, Sondore D, Kumsars I, Jegere S, Narbute I, Grave A, Zakke I, Erglis A, Mihaylov G, Marenzi G, Timoteo AT, Assanelli E, Ferrari C, Marana I, Lauri G, De Metrio M, Grazi M, Campodonico J, Moltrasio M, Bartorelli AL, Martins H, Valente B, Saraiva F, Baptista R, Jorge E, Mendes PL, Monteiro P, Costa S, Franco F, Providencia LA, Saeed M, Gaber R, Oliveira JA, Mornos C, Cozma D, Pescariu S, Dragulescu SI, Kamal HS, Abdelfattah A, Abdelbary AM, Elassar H, Naggar A, Khaled M, Ferreira ML, Fareed AM, Pernes JM, Gaux JC, Oraby M, Nasr GM, Maklady F, Dupouy P, Prull MW, Sasko B, Wirdemann H, Ferreira RC, Bittlinsky A, Butz T, Trappe HJ, Perazzolo Marra M, Cacciavillani L, Marzari A, De Lazzari M, Turri R, China P, Corbetti F, Villanueva Benito I, Iliceto S, Stazhadze LL, Spiridonova EA, Bulanova NA, Ermolaev AA, Savic L, Mrdovic I, Krljanac G, Perunicic J, Asanin M, Solla I, Lasica R, Matic M, Vasiljevic Z, Ostojic M, Pudil R, Tichy M, Blaha V, Andrys C, Vojacek J, Conti A, Paredes E, Poggioni C, Viviani G, Bulletti F, Boni V, Luzzi M, Vicidomini S, Donati M, Del Taglia B, Pini R, Sousa O, Diaz Castro O, Fontes-Carvalho R, Caeiro D, Dias Ferreira N, Silva G, Pereira E, Ribeiro J, Albuquerque A, Gama Ribeiro V, Murai M, Takeda Y, Calvo F, Shinmyo T, Tanigawa J, Hazui H, Nakakohji T, Ohishi Y, Hoshiga M, Ishihara T, Hanafusa T, Belohlavek J, Rohn V, Baz JA, Kunstyr J, Lips M, Semrad M, Horak J, Mlejnsky F, Tosovsky J, Linhart A, Lindner J, Sablik Z, Samborska-Sablik A, Iniguez A, Drozdz J, Gaszynski W, Ferrer Hita JJ, Rodriguez-Gonzalez A, Izquierdo-Gomez MM, Enjuanes-Grau C, Rubio-Iglesias-Garcia C, Sanchez-Grande-Flecha A, Juarez-Prera R, Blanco-Palacios G, Aleksova A, Bosa-Ojeda F, Marrero-Rodriguez F, Lakhdar R, Drissa M, Drissa M, Jedaida B, Drissa H, Sousa O, Dias Ferreira N, Sampaio F, Gerloni R, Caeiro D, Fontes-Carvalho R, Silva G, Pereira E, Ribeiro J, Albuquerque A, Gama Ribeiro V, Hsin HT, Huang JH, Chiu KM, Belfiore R, Chen ZS, Lin PC, Chen LY, Chu SH, Efthimiadis I, Skendros P, Sarantopoulos A, Boura P, Delewi R, Nijveldt R, Carriere C, Van Der Laan AM, Hirsch A, Van Der Vleuten PA, Klees M, Tijssen JGP, Zijlstra F, Van Rossum AC, Piek JJ, Backus BE, Six AJ, Barbati G, Kelder JH, Mosterd A, Mast EG, Mast TP, Braam R, Tio R, Veldkamp R, Doevendans PA, Delewi R, Nijveldt R, Fabris E, Van Der Laan AM, Hirsch A, Van Der Vleuten PA, Klees M, Tijssen JGP, Zijlstra F, Van Rossum AC, Piek JJ, Paarup Dridi N, Holmvang L, Possa F, Engstroem T, Rekik S, Brunet J, Hager FX, Bayet G, Meille L, Quatre JM, Sainsous J, Chu PH, Tang CH, Nait D, Ibatov A, Pogosova N, Koltunov IE, Sapunova ID, Vigodin VA, Uhliar R, Gilis-Januszewski T, Mellwig KP, Wiemer M, Gilis-Januszewski J, Milo M, Peterschroeder A, Schmidt A, Brockmeyer B, Horstkotte D, Suzuki A, Eki Y, Higuchi H, Yukawa A, Yamauchi R, Sato Y, Sinagra G, Endo Y, Martinez Garcia V, Salazar Mendigucha Garcia J, Ariza Sole A, Sanchez Salado JC, Lorente Tordera V, Homs Vila S, Gomez Hospital JA, Cequier Fillat A, Esplugas Oliveras E, Marques N, Andion Ogando R, Hernandez Luis C, Sandin Fuentes M, Tapia Ballesteros C, Vegas Valle JM, Gonzalez Garcia IA, Duro Aguado IA, Palomino Doza AJ, Gomez Salvador I, San Roman Calvar JA, Mimoso J, Nikishin AG, Mamarasulov TM, Pirnazarov MM, Koracevic G, Pavlovic M, Glasnovic J, Damjanovic M, Stojkovic A, Kostic T, Todorovic L, Gomes V, Petrovic S, Zivkovic M, Djordjevic-Radojkovic D, Cherneva ZCH, Denchev SD, Heltai K, Becker D, Merkely B, Nikulina N, Yakushin SS, Agra Bermejo RM, Akinina SA, Furmenko GI, Boytsov A, Yakushin SS, Nikulina NN, Furmenko GI, Akinina SA, Dores H, Leal S, Rosario I, Emad Abu Assi EAA, Bronze L, Abecasis J, Correia MJ, Arroja I, Fonseca C, Aleixo A, Silva A, Dores H, Leal S, Rosario I, Sergio Raposeiras Roubin SRR, Monge J, Abecasis J, Correia MJ, Bronze L, Arroja I, Aleixo A, Silva A, Rosario I, Leal S, Dores H, Pilar Cabanas Grandio PCG, Correia MJ, Monge JC, Abecasis J, Arroja I, Aleixo A, Silva A, Palmisano P, Zaccaria M, Zanna D, Marangelli V, Carlos Pena Gil CPG, Caiati C, Ciccone MM, Favale S, Picon Heras R, Loureiro MJ, Nunez-Gil I, Garcia Rubira JC, Acebal C, Ruiz-Mateos B, Ibanez B, Jose Maria Garcia Acuna JMGA, Fernandez-Ortiz A, Macaya C, Rosario I, Dores H, Leal S, Monge JC, Correia MJ, Bronze Carvalho L, Arroja I, Fonseca C, Jose Ramon Gonzalez Juanatey JRGJ, Aleixo A, Silva A, Urazovskaya I, Vinogradova D, Vasilieva E, Shpektor A, Faustino A, Seca L, Barra S, Providencia R, Daly MJ, Silva J, Gomes P, Costa G, Caetano F, Costa M, Leitao-Marques A, Conti E, Musumeci MB, Lauri FM, Dito E, Scott P, De Giusti M, Lallo A, Fusco D, Davoli M, Volpe M, Autore C, Gamra H, Dridi Z, Hassine M, Addad F, Owens CG, Gherissi I, Reda A, Mahjoub M, Bouraoui S, Abdennadher M, Betbout F, Mota PMFP, Silva JD, Providencia RA, Leitao-Marques A, Tomlin A, Nikolic Heitzler V, Babic Z, Milicic D, Bergovec M, Raguz M, Mirat J, Strozzi M, Plazonic Z, Giunio L, Steiner R, Smith B, Stanojevic D, Apostolovic S, Jankovic Tomasevic R, Pavlovic M, Djordjevic V, Djordjevic Radojkovic D, Salinger Martinovic S, Koracevic G, Damjanovic M, Ilic I, Adgey AAJ, Scafa Udriste A, Fruntelata A, Gainoiu E, Bogdan S, Calmac L, Zamfir D, Teodorescu C, Guran M, Constantinescu D, Dorobantu M, Alvarez-Contreras LR, Rosario I, Dores H, Leal S, Abecasis J, Monge JC, Bronze L, Arroja I, Fonseca C, Aleixo A, Silva A, Juarez U, Konopka A, Banaszewski M, Wojtkowska I, Stepinska J, Vidergold JV, Osipova IV, Tavrovskaya TV, Galkina JV, Timofeev AV, Vorobyov RI, Altamirano A, Vorobyova EN, Matos L, Carvalho ACC, Oliveira W, Cintra F, Poyares D, Andersen M, Martins R, Tufik S, Neuzil P, Arias A, Ostadal P, Skoda J, Holy F, Holdova K, Brada J, Horakova S, Mlcek M, Hrachovina V, Kittnar O, Gorudko IV, Alvarez-San Gabriel A, Buko IV, Cherenkevich SN, Polonetsky LZ, Plotkin VY, Timoshina MA, Azanchevskaya SV, Chromov-Borisov NN, Vorlat A, Snoep L, Claeys MJ, Gonzalez-Pacheco H, Vrints CJ, Palazzuoli A, Caputo M, Quatrini I, Calabro A, Antonelli G, Campagna MS, Franci B, Nuti R, Maisel A, Martinez-Sanchez C, Paulo C, Mascarenhas J, Patacho M, Pimenta J, Bettencourt P, Negrini M, Minora T, Marino P, Seregni R, Tavlueva E, Rahnavardi M, Barbarash O, Barbarash L, Janota T, Kudlicka J, Malik K, Wichterle D, Hradec J, Faria R, Mimoso J, Marques N, Keshtkar-Jahromi M, Trigo J, Marques V, Gomes V, Body R, Carley SD, Mcdowell G, Nuttall M, Wibberley C, France M, Cruickshank JK, Vakili H, Mackway-Jones K, Cavusoglu Y, Cavusoglu A, Unluoglu I, Tek M, Demirustu C, Unalacak M, Gorenek B, Birdane A, Yuksel F, Gholamin S, Ata N, Leon M, Cozma C, Mitu F, Matos L, Carvalho ACC, Almeida DR, Oliveira W, Dias CB, Barra SNC, Razavi SM, Gomes P, Silva J, Providencia R, Seca L, Leitao Marques A, Burazor I, Burazor M, Krstic M, Lazovic M, Stojkovic A, Gilis-Januszewski T, Vukmanovic M, Djordjevic J, Radovanovic Z, Ilic D, Bosnjakovic P, Margato R, Ferreira AC, Mateus PS, Ribeiro H, Fontes P, Mellwig KP, Moreira JI, Teixeira T, Silva JD, Costa M, Leitao-Marques A, Conte G, Menozzi A, Solinas E, Bolognesi MG, Tadonio I, Wiemer M, Mantovani F, Cattabiani A, Vignali L, Ardissino D, Scafa Udriste A, Fruntelata A, Tautu O, Calmac L, Alexandrescu A, Niculescu R, Gilis-Januszewski J, Tatu-Chitoiu G, Dorobantu M, Djordjevic Radojkovic D, Apostolovic S, Perisic Z, Damjanovic M, Jankovic R, Salinger Martinovic S, Koracevic G, Todorovic L, Peterschroeder A, Bozinovic N, Matos L, Carvalho ACC, Almeida DR, Oliveira W, Dias CB, Santos C, Ferreira J, Carmo P, Costa F, Koerfer J, Brito J, Sousa P, Cardoso G, Correia I, Aguiar C, Silva A, Fountoulaki K, Kastellanos S, Voltirakis E, Kokotos A, Horstkotte D, Michalakeas C, Kontsas K, Hasioti K, Iliodromitis ET, Anastasiou-Nana M, Andion Ogando R, Hernandez Luis C, Sandin Fuentes MG, Tapia Ballesteros C, Vegas Valle JM, Vrsalovic M, Zatarain Nicolas E, Amat Santos IJ, Martinez Uruena N, Alvarado Montes De Oca M, San Roman Calvar JA, Belohlavek J, Dytrych V, Kovarnik T, Smid O, Kral A, Getaldic B, Linhart A, Aroutunov AG, Intwala S, Sondore D, Juhnevica D, Trusinskis K, Strenge K, Jegere I, Narbute I, Grave A, Vrkic N, Erglis A, Shaalan HSH, Pagava Z, Agladze R, Shakarishvili R, Sharashidze N, Gujejiani L, Saatashvili G, Martins H, Saraiva F, Pintaric H, Baptista R, Jorge E, Mendes PL, Monteiro P, Costa S, Franco F, Providencia LA, Gaber R, Gaber R, Hristova K, Khan S, Katova TZ, Kostova V, Simova Y, Parepa I, Suceveanu AI, Suceveanu A, Mazilu L, Voinea FL, Craiu E, Obradovic S, Wasan B, Salinger S, Vukotic S, Rafajlovski S, Romanovic R, Koracevic G, Antonijevic N, Gligic B, Hutyra M, Skala T, Horak D, Moretti L, Vindis D, Taborsky M, Contine A, Del Pinto M, Angeli F, Verdecchia P, Borgognoni F, Grikstaite E, Pantano P, Ambrosio G, Grossi P, Cavallini C, Bonanad C, Sanchis J, Bodi V, Nunez J, Bosch X, Heras M, Pellicer M, Llacer A, Seca LF, Silenzi S, Fontes-Carvalho R, Caeiro D, Adao L, Oliveira M, Goncalves H, Primo J, Gama V, Fresco C, De Biasio M, Sappa R, Testa M, Muser D, Morocutti G, Bernardi G, Proclemer A, Lombardi C, Metra M, Bugatti S, Pasotti E, Quinzani F, Adamo M, Candelori L, Villa C, Rovetta R, Manerba A, Dei Cas L, Mariani M, Dushpanova A, Baroni M, Cerone E, Nardelli A, Gianetti J, Clementi LN, Berti S, Timoteo AT, Oliveira MM, Silva MN, Toste A, Ramos R, Cunha PS, Feliciano F, Soares R, Santos S, Forlini M, Ferreira RC, Ostadal P, Kruger A, Vondrakova D, Herget J, Di Maio RC, Navarro C, Cromie NA, Anderson JMC, Adgey JAA, Lando L, Tadel-Kocjancic S, Radsel P, Knafelj R, Gorjup V, Noc M, Caeiro Pereira D, Braga P, Fontes Carvalho R, Sousa O, Rodrigues A, Pezzuoli ML, Goncalves H, Ribeiro J, Goncalves M, Simoes L, Gama V, Borisov KV, Corradetti P, Leurent G, Pennec PY, Filippi E, Moquet B, Hacot JP, Druelles P, Rialan A, Rouault G, Coudert I, Le Breton H, Gevaert S, Tromp F, Vandecasteele E, De Somer F, Van Belleghem Y, Bouchez S, Martens F, Herck I, De Pauw M, Spinar J, Ludka O, Sepsi M, Miklik R, Dusek L, Tomcikova D, Marques N, Mimoso J, Gomes V, Garcia-Acuna JM, Aguiar-Souto P, Raposeiras Roubin S, Agra-Bermejo R, Jacquet M, Abu-Assi E, Gonzalez-Juanatey JR, Ibatov A, Labrova R, Spinar J, Karlik R, Kanovsky J, Lokaj P, She Q, Deng SB, Huang SH, Gu LJ, Rong JIAN, Wu ZK, Li Y, Zhang J, Parascan L, Campanile A, Spinelli L, Santulli G, Ciccarelli M, De Gennaro S, Assante Di Panzillo E, Trimarco B, Iaccarino G, Bobescu E, Radoi M, Datcu G, Dobreanu D, Doka B, Charniot JC, Cosson C, Albertini JP, Bittar R, Giral P, Cherfils C, Guillerm E, Bonnefont-Rousselot D, Craiu E, Rusali A, Cojocaru L, Parepa I, Koizumi T, Iida S, Sato J, Kikutani T, Muramatsu T, Nishimura S, Komiyama N, Lee WP, Ong BB, Haralambos K, Townsend D, Rees JAE, Williams EJ, Halcox JP, Mcdowell I, Damjanovic M, Koracevic G, Djordjevic-Radojkovic D, Pavlovic M, Krstic N, Ciric-Zdravkovic S, Stojkovic A, Perisic Z, Apostolovic S, Faustino A, Seca L, Barra S, Caetano F, Providencia R, Silva J, Gomes P, Costa G, Costa M, Leitao-Marques A, Volkova AL, Arutyunov GP, Bylova NA, Dayter II, Jao YTFN, Fang CC, Chen Y, Yu CL, Wang SP, Valencia J, Perez-Berbel P, Ruiz-Nodar JM, Pineda J, Bordes P, Quintanilla M, Mainar V, Sogorb F, Santos N, Serrao M, Cafe H, Silva B, Oliveira R, Caires G, Drumond A, Araujo J, Providencia RA, Gomes PL, Seca L, Barra S, Silva J, Faustino A, Caetano F, Pais JR, Mota P, Leitao-Marques AM, Farhan S, Jarai R, Tentzeris I, Vogel B, Freynhofer MK, Wojta J, Huber K, Poli M, Trambaiolo P, Corsi F, De Luca M, Mustilli M, Lukic V, Simonetti M, Ferraiuolo G, Lettino M, Casella G, Conte MR, De Luca L, Geraci G, Ceravolo R, Milo M, Pani A, Trambaiolo P, Fradella G, Schratter A, Thiele H, Klemm T, Demmin K, Lehmann D, Mende M, Schuler G, Pittl U, Chernova A, Nikulina SU, Naruke T, Inomata T, Yanagisawa T, Maekawa E, Mizutani T, Shinagawa H, Nishii M, Takeuchi I, Takehana H, Izumi T, Paulo C, Mascarenhas J, Patacho M, Pimenta J, Bettencourt P, Nardai S, Szabo GY, Berta B, Edes I, Merkely B, Delgado Silva J, Seca L, Baptista R, Providencia R, Mota P, Costa M, Leitao-Marques A, Faria R, Trigo J, Gago P, Mimoso J, Marques N, Gomes V, Gheorghe G, Nanea IT, Cristea A, Almarichi S, Martins H, Saraiva F, Baptista R, Jorge E, Mendes PL, Monteiro P, Costa S, Franco F, Providencia LA, Nanea T, Gheorghe GS, Visan S, Paun N, Gaber R, Gaber R, Delewi R, Nijveldt R, De Bruin HA, Hirsch A, Van Der Laan A, Bouma BJ, Tijssen JPG, Van Rossum AC, Zijlstra F, Piek JJ, Rus H, Radoi M, Donea M, Ciurea C, Ifteni G, Casolo G, Chioccioli M, Magnacca M, Del Meglio J, Comella A, Baratto M, Lera J, Salvadori L, Tessa C, Vignali C, Keca Z, Momcilov Popin T, Panic G, White R, Mateen F, Weaver A, Dragu R, Agmon Y, Kapeliovich M, Hammerman H, Timoteo AT, Lousinha A, Santos N, Oliveira JA, Ferreira ML, Ferreira RC, Okisheva E, Tsaregorodtsev D, Sulimov V, Amat Santos IJ, Gonzalez IA, Hernandez C, Sandin MG, Tapia C, Andion R, Alvarado M, Campo A, San Roman JA, Fredman D, Svensson L, Rosenqvist M, Tadel-Kocjancic S, Radsel P, Knafelj R, Gorjup V, Noc M, Zima E, Jenei ZS, Kovacs E, Osztheimer I, Szabo GY, Molnar L, Horvath A, Becker D, Geller L, Merkely B, Maggi R, Furukawa T, Viscardi V, Brignole M, Leal SRN, Dores H, Rosario I, Monge J, Carvalho MJ, Arroja I, Leitao A, Fonseca C, Aleixo A, Silva A, Keuleers S, Herijgers P, Herregods MC, Budts W, Dubois C, Meuris B, Verhamme P, Flameng W, Van De Werf F, Adriaenssens T, Badran H, Elnoamany M, Lolah T, Tatu-Chitoiu G, Dorobantu M, Benedek I, Craiu E, Sinescu C, Ionescu DD, Olariu C, Radoi M, Pop C, Macarie C, Mollik MAH, Hassan AI, Paul TK, Haque MZ, Jahan R, Rahmatullah M, Khatun MA, Rahman MT, Chowdhury MH, Bustamante Munguira J, Tamayo E, Garcia-Cuenca I, Bustamante E, Gualis J, Gomez-Martinez ML, Florez S, Gomez-Herreras JI, Ramirez Rodriguez R, Ramirez Rodriguez AM, Garcia-Bello MA, Hernadez Ortega E, Caballero Dorta E, Garcia Quintana A, Piro Mastraccio V, Medina Fernandez Aceytuno A, Assanelli E, De Metrio M, Rubino M, Lauri G, Cabiati A, Campodonico J, Grazi M, Moltrasio M, Marana I, Marenzi G, Lovlien M, Schei B, Picon-Heras R, Acebal C, Garcia Rubira JC, Vivas Balcones D, Nunez-Gil I, Ruiz-Mateos B, Ibanez B, Fernandez-Ortiz A, Vintila VD, Enescu OA, Stoicescu CI, Udroiu C, Cinteza M, Tatu - Chitoiu G, Vinereanu D, Fresco C, De Biasio M, Muser D, Sappa R, Morocutti G, Bernardi G, Proclemer A, Fontanella B, Affatato A, Ciccarese C, Sacchini M, Volpini M, Bianchetti F, Verzura G, Dei Cas L, Pudil R, Blaha V, Vojacek J, Paraskevaidis I, Ikonomidis I, Parissis J, Papadopoulos C, Stasinos V, Bistola V, Anastasiou-Nana M, Shochat M, Shotan A, Kazatsker M, Gurovich V, Asif A, Noiman E, Levy Y, Blondhaim D, Rabinovich P, Meisel S, Koracevic G, Stojkovic A, Petrovic S, Pavlovic M, Glasnovic J, Tomasevic M, Krstic N, Djordjevic-Radojkovic D, Sakac D, Obradovic S, Londono Sanchez O, Pacreu S, Torres L, Mihaylov G, Shaban GM, Trendafilova E, Krasteva V, Mudrov TS, Didon JP, Panageas V, Vlachos N, Pernat A, Radan I, Mozina H, Izzo A, Tomasi L, Mantovani P, Dall'oglio L, Pepi P, Romano M, Cionini F, Baccaglioni N, Zanini R, Viertel A, Havers J, Ballard G, Groenefeld G, Santos N, Branco LM, Oliveira JA, Ferreira L, Timoteo AT, Fiarresga A, Feliciano J, Ramos R, Ferreira RC, Izzo A, Tomasi L, Mantovani P, Pepi P, Lettieri L, Dall'oglio L, Reggiani A, Zanini R, Garcia Gonzalez MJ, Arroyo Ucar E, Hernandez Garcia C, Juarez Prera R, Blanco Palacios G, Dorta Martin M, Marrero Rodriguez F, Martin AC, Manzo Silberman S, Chaib A, Varenne O, Allouch P, Salengro E, Jegou A, Margot O, Spaulding C, Diego A, De Miguel A, Cuellas C, Fraile E, Martin J, Vega B, Bangueses R, Fernandez-Vazquez F, Perez De Prado A, Rosario I, Dores H, Leal S, Correia MJ, Monge JC, Arroja I, Abecasis J, Aleixo A, Silva A, Dragu R, Agmon Y, Kapeliovich M, Hammerman H, Garcia-Garcia C, Subirana I, Sala J, Bruguera J, Valle V, Sanz G, Fiol M, Aros F, Marrugat J, Elosua R, Barra SNC, Silva J, Gomes P, Providencia R, Seca L, Leitao Marques A, Zhao ZY, Wu YJ, Li JJ, Yang YJ, Xu B, Tang YD, Song GY, G RL, Panic M, Milicevic P, Stankovic I, Ilic I, Kafedzic S, Kalezic T, Milicevic D, Aleksic A, Putnikovic B, Neskovic A, Serpytis P, Rucinskas K, Kalinauskas A, Karvelyte N, Santos De Sousa CI, Ferreira S, Calaca J, Lousada N, Palma Reis R, Gualandro DM, Seguro LFBC, Braga FGM, Silvestre OM, Lage RL, Fabri J, Oliveira MT, Urbano Moral JA, Torres Llergo J, Solanilla Rodriguez R, Sanchez Gonzalez A, Martinez Martinez A, Den Uil CA, Lagrand WK, Van Der Ent M, Jewbali LSD, Cheng JM, Spronk PE, Simoons ML, Mornos C, Petrescu L, Dragulescu D, Ionac A, Guardado J, Azevedo O, Fernandes M, Canario-Almeida F, Sanfins V, Pereira A, Almeida J, Kaplunova VU, Belenkov YN, Privalova EV, Fomin AA, Suvorov AY, Goodkova A, Rubakova MG, Kuznetsova IA, Semernin EN, Keshavarzi F, Kojuri J, Mikhailov VM, Vezhenkova IV, Goodkova AYA, Jarai R, Pavlovic I, Farhan S, Schwarz M, Jakl G, Huber K, Jarai R, Schwarz M, Smetana P, Jakl G, Perkmann T, Farhan S, Huber K, Mayr A, Mair J, Klug G, Schocke M, Trieb T, Jaschke W, Pachinger O, Metzler B, Bronze Carvalho L, Azevedo J, Andrade ML, Arroja I, Relvas MJ, Coucello J, Monge J, Morais G, Seabra M, Aleixo A, Afamefule F, Luaces Mendez M, Teijeiro-Mestre R, Nunez-Gil IJ, Leco-Gil N, Madronal-Cerezo E, Zannin I, Ruiz J, Orynchak MA, Vakalyuk II, Vakalyuk IP, Berezin A, Panasenko T, Cavusoglu Y, Cavusoglu A, Unluoglu I, Tek M, Demirustu C, Gorenek B, Unalacak M, Birdane A, Yuksel F, Ata N, Lee WP, Halcox JPJ, Cavusoglu Y, Beyaztas A, Entok E, Demirustu C, Uslu I, Birdane A, Gorenek B, Ata N, Schaefer A, Flierl U, Seydelmann N, Bauersachs J, Calmac L, Craiu E, Ionescu DD, Nanea T, Pop C, Marinescu S, Macarie C, Tatu Chitoiu G, Fruntelata AG, Dorobantu M, Hamdi S, Maazoun Y, Neji A, Farhat O, Majdoub M, Ben Hamda K, Maatouk F, Balanescu SM, Benedek I, Nedelciuc I, Deleanu D, Dobreanu D, Olinic D, Petrescu L, Ortan F, Mot S, Tatu Chitoiu G, Sinnaeve PR, Moreels S, Adriaenssens T, Dubois C, Coosemans M, Vydt T, Desmet W, Sinnaeve PR, Moreels S, Vydt T, Dubois C, Adriaenssens T, Coosemans M, Desmet W, Poli M, Trambaiolo P, Corsi F, De Luca M, Mustilli M, Lukic V, Simonetti M, Ferraiuolo G, Tobing D, Rifnaldi R, Juzar D, Firdaus I, Dharma S, Irmalita I, Kalim H, Bejiqi R, Retkoceri R, Bejiqi H, Kryeziu L, Kelmendi M, Borovci SH, Victor SM, Gnanaraj A, Deshmukh R, Mullasari AS, Yahalom M, Kaiyal RS, Roguin N, Bornstein J, Atar S, Farah R, Seca LF, Faustino A, Silva J, Providencia R, Gomes P, Barra S, Caetano F, Costa M, Leitao Marques AM, Margato R, Sousa P, Ribeiro H, Rocha L, Correia A, Moreira JI, Carvalho HC, Afifi M, Abed N, Santos N, Serrao M, Cafe H. Abstracts. Eur Heart J Suppl 2010. [DOI: 10.1093/eurheartj/suq023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|